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At present, Drug-Induced Liver Injury (DILI) is the most frequent cause of acute liver injury, 
with an incidence ranging from 0.023-1.5‰ in developed countries. DILI can be separated 
into two different types. Whereas intrinsic DILI concerns predictable dose-dependent 
hepatoxicity, idiosyncratic DILI refers to unpredictable adverse drug reactions for which there 
is no existing pharmacological explanation. Many prescription and over-the-counter drugs 
causing DILI do so in an undiscovered and idiosyncratic pattern. It is the latter that causes DILI 
to be the most frequent cause of safety-related drug withdrawals. This causes delays in the 
availability of treatments and is responsible for 20% to 40% of liver transplants and hepatic 
failures. While several mechanisms might be responsible for idiosyncratic DILI, a broad 
industry-wide consensus was reached in 2016 on the importance of the liver bile salt export 
pump (BSEP) and the need to test for BSEP inhibition at an early stage of drug development.  
An assay for BSEP-mediated bile acid transport was established to study the biochemical 
mechanisms of inhibition of BSEP activity by organic compounds. The four selected 
compounds showed competitive inhibition of taurocholate transport in Lineweaver-Burk 
plots but also other types of inhibition in Eadie-Hofstee plots. These results indicate that these 
inhibitors might compete with taurocholate for binding in the substrate-binding pocket and 
possibly, that the inhibitors are transported by BSEP. Interestingly, this work shows a strong 
inhibitory effect of excess Mg2+ on the ability of BSEP to transport glycocholic acid; the 
transport of taurocholic acid was not inhibited by Mg2+. To get more insight in structure-
function relationships in BSEP, a condense and accurate database of all known BSEP point 
mutations from published literature was compiled. This database shows a total of 264 known 
mutations associated with several pathogenic and non-pathogenic phenotypes. To date, 
there is still little known about the effects of many of these mutations on BSEP activity. Only 
82 of the 264 mutations have currently been investigated for their impact on function and 
expression level of BSEP.  
 
IX 
2D and 3D primary cultured hepatocytes were used to establish the effect of DILI-inducing 
drugs on the synthesis of bile acids and their distribution across the cell and the media. 
Multivariate analyses of the data demonstrate that drugs can change the bile acid 
composition in hepatocytes and their environment. This might occur by regulating bile acid 
synthesis pathways and/or by modulating the selectivity of BSEP itself. Interestingly, some of 
the detected changes in bile acid concentrations might be early indicators of cell stress and 
cell death. The experiments also suggest that drugs can cause a change in BSEP expression in 
the plasma membrane, through changes in the trafficking of protein to and from the plasma 
membrane. These changes could explain the existence of non-pathogenic BSEP inhibitors. 
These findings increase our understanding of the influence of compounds on bile acid 
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To maintain their viability, all cells continually need to import nutrients and export toxic 
waste. For this purpose, cells express a wide range of membrane transporters that are 
embedded in the plasma membrane and mediate the movement of their substrates across 
this permeability barrier. One important superfamily of transport proteins in prokaryotic, 
eukaryotic and plant cells, involved in this process, is that of the ATP binding cassette (ABC) 
transporters [1]. These transporters comprise two nucleotide-binding domains (NBDs) and 
two membrane domains (MDs) and sometimes contain additional domains. ABC transporters 
are able to transport a broad range of compounds from simple ions, through polar, 
amphipathic and hydrophobic organic molecules to peptides, complex lipids and even small 
proteins. [2]. Since the discovery of the first known mammalian multidrug ABC transporter P-
glycoprotein (also referred to as ABCB1) in 1974 [3], 47 other members of the superfamily 
have been identified in mammals [4]. These transporters have a standardized nomenclature 
consisting of subfamily and specified gene name based on their sequence and common 
architecture.  
This thesis will focus on the mammalian ABC transporter ABCB11, also referred to as the bile 
salt export pump (BSEP). BSEP is specifically expressed in the liver and is predominantly 
present in the apical membrane of hepatocytes where it is one of the most abundant 
canalicular efflux transporters [5]. Bile acids are produced in the liver and released as bile into 
the intestines, after which 95% bile acids are  reabsorbed in the terminal ileum and recycled 
back to the liver [6]. This efficient enterohepatic circulation of bile acids plays an important 
role in liver function, metabolic regulation and liver physiology. Bile contains an intricate 
mixture of endogenous bile salts, bilirubin, phospholipids, cholesterol, amino acids, steroids, 
enzymes, porphyrins, vitamins and heavy metals as well as exogenous, xenobiotics and 
environmental toxins. Bile functions as a powerful detergent that facilitates lipid and nutrition 
absorption as well as cholesterol and toxic metabolite excretion [7]. Due to the hydrophobic 
characteristics of bile acids, their accumulation in the hepatocytes would cause cell 
membrane damage, impair liver function and lead to cholestasis and cirrhosis. The 
accumulation of bile acids often leads to drug induced liver injury (DILI). In 10% of cases, DILI 
is associated with acute hepatitis, which is the most frequently cited reason for safety-related 




increased health care costs but is also a major economic challenge to the pharmaceutical 
industry. Many prescription and over-the-counter drugs causing DILI do so with an 
undiscovered and idiosyncratic pattern. The annual incidence of DILI is between 10 and 15 
per 10,000 to 100,000 patients using prescribed medicines [7,10–12]. Due to this low 
frequency, compounds causing severe DILI are challenging to identify in clinical trials and 
often remain unidentified until post-marketing monitoring when the drug has become 
available to a larger population. Initial cell stress in the liver can be caused by a wide range of 
mechanisms including inhibition of hepatocellular function, e.g. canalicular bile salt secretion, 
through inhibition of the BSEP activity [13]. Understanding the working mechanisms of BSEP 
and its interactions with therapeutic drugs will help to avoid DILI and is also relevant in the 
development of new screening assays and treatments methods for Progressive familial 
intrahepatic cholestasis type 2 (PFIC2). However, current knowledge about BSEP is very sparse 
and more research into the molecular mechanisms of this pump is therefore necessary. 
This introduction will: 
• provide a summary of current standards in pharmacovigilance (Section 1.1),  
• highlight the current understanding of bile acid production and functions (Section 1.2),  
• summarize current insights in the regulation and activity of BSEP (Section 1.3), 













Pharmacovigilance is defined by the World Health Organisation as: “the process and science 
of monitoring the safety of medicines and taking action to reduce the risks and increase the 
benefits of medicines”. The time for developing a new drug from idea to market launch can 
take between 12-15 years and costs over $1 billion [14]. The international council for 
harmonisation of technical requirements for pharmaceuticals for human use (ICH) has set a 
series of guidelines regarding quality, safety, efficacy and multidisciplinary science regarding 
drug safety (https://www.ich.org/products/guidelines.html). Most pharmaceutical and drug 
regulatory agencies like the USA Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) adhere to these pre-set guidelines. In recent years, research has 
streamlined the selection procedure of compounds before entering the clinical testing stages, 
containing several compound safety checks along the way. Drug development can be 
summarised into the following four steps and consists of drug discovery, pre-clinical 
development, clinical development and regulatory approval (see Figure 1). Each step contains 
a subset of tests that needs to be passed before the compound can advance to the next stage. 
While pre-clinical assays are relatively cheap, starting from the in-vivo stage, the money spent 
on testing and advancing compounds increases steadily. The pharmaceutical industry, 
therefore, attempts to discriminate drugs with a high propensity to cause idiosyncratic 
adverse drug reactions from those with a low propensity to cause such reactions, by profiling 






Figure 1. Summary of the different stages during drug development. The inversed pyramid indicates the 























•Phase I: Effect on body and safety in humans
•Phase II: Effectiveness against diseases











1.1.1 Pre-clinical development. 
Stage I: in-vitro testing 
To optimise the safety of a drug, the compound is tested for carcinogenicity, genotoxicity 
toxicokinetic and pharmacokinetics, toxicity, reproductive toxicology, photo safety, 
nonclinical paediatric safety and immunotoxicity among others. Different in vitro assays have 
been developed to test for each one of these, but in many cases, there is still a requirement 
to test on animals before a drug is allowed onto the market. The first round of preclinical risk 
assessment incorporates in-vitro assays. At present, AstraZeneca uses five different tests to 
identify harmful compounds that should be removed from the development pipeline [15]. 
The panel consists of: 1.) Toxicity to Transformed Human Liver Epithelial (THLE) cells that do 
not express cytochrome P450 enzymes, 2.) Toxicity to THLE cells that selectively express 
cytochrome P450 3A4, to estimate drug metabolism-mediated toxicity, 3.) Cytotoxicity in 
HepG2 cells in glucose and galactose media, which is indicative of drug-induced mitochondrial 
injury, 4.) Inhibition of human BSEP (hBSEP) in ISOVs, and 5.) Inhibition of the rat multidrug 
resistance associated protein 2 (MRP2) in ISOVs [16], a protein capable of transporting some 
bile salts. Additionally, the covalent binding (CVB) burden is estimated by determining the 
irreversible covalent binding of a radiolabelled compound to human hepatocytes and 
factoring in both the maximum prescribed daily dose and the fraction of metabolism leading 
to CVB [15]. 
Each of these tests individually has a low selectivity to identify potentially harmful compounds 
but together and combined with the CVB burden, these tests have a sensitivity of 48% and a 
specificity of 89% [15]. Sensitivity and specificity are terms used in the evaluation of clinical 
tests. To calculate the sensitivity and specificity, researchers use i.) True positives: the number 
of compounds the assay correctly identifies to cause DILI. ii.) False positives: the number of 
compounds where the assay falsely identifies a compound to cause DILI. iii.) True negatives: 
the assay correctly identifies the compound not to cause DILI and iv.) False negatives: the 
assay falsely identifies a compound to cause DILI. Accordingly, the sensitivity describes an 
assay’s ability to correctly test which compounds will cause DILI, and the specificity describes 
an assay’s ability to correctly identify which compounds do not cause DILI [17]. Thus, while 
the described assay panel can identify 84% of the compounds that do not cause DILI, it is only 




There are several limitations in these types of experiments. The selection of human samples 
causes several issues: 1.) Most established cell lines originate from cancer cell lines that have 
a completely different protein expression and metabolomic activity compared to normal cells 
in healthy humans. Studies have shown that primary human hepatocytes (PHH) are the best 
choice for cell culturing [18], but have the drawback that they are expensive to obtain and 
that they do not further proliferate. 2.) In vitro cultured cells are often monocultures and do 
not come into contact with other cells that are responsible for mitigating or activating toxic 
effects of drugs. These cells therefore only provide partial information regarding the human 
as a whole organism. Yet, alternatives are available such as co-cultures of hepatocytes with 
nonparenchymal cells or Kupffer cells, but experiments with such co-cultures are often 
challenging both technically and in terms of interpretation of data [19] 3.) Moreover, cells 
cultured in in vitro layers rather than the in vivo 3D structures have significant differences in 
gene, protein, and P450 enzyme expression [20], all lead to significant deviations from in vivo 
responses. 
Stage II: in-vivo testing 
The second part of pre-clinical development is the in vivo testing of compounds. While EMA 
supports the implementation of the 3R principle, animal data on drug safety is still a hard 
requirement before a drug is allowed into clinical trials. The 3R principle describes the 
Replacement, Reduction and Refinement of animal research, specifically in that order. 
However, basic animal research findings only translates for about ~10% to the human clinical 
research [21] and 96% of drugs that pass preclinical tests (including animal research) fail to 
get market approval [22]. It is, therefore, necessary to carefully asses and draw conclusions 
from animal data regarding drug safety. There are two types of animal experimentation: a.) 
Basic, investigating the basic biology of human diseases and b.) Applied: describing drug 
research and development and, toxicity and safety testing. Irrelevant to the category, the 
conclusions of these experiments are often used to form conclusions regarding human 
biology or health sciences. Human hepatocytes have for example a lower capacity than rat 
hepatocytes to secrete bile acids back into blood. It was suggested that this reduced fractional 
elimination rate at the sinusoidal membrane contributes to a higher susceptibility towards 





While there are several issues with animal testing, drug safety assessment in animals has been 
hugely successful considering that the last lethal phase 1 test occurred in 2006 with 
Theralizumab by PAREXEL [24]. It is, however, vital to develop the preclinical testing to save 
animal lives and money.  
1.2 Bile acid production and the enterohepatic pathway 
Bile acids are produced in the liver and then released into the intestines. Bile acids are later 
recycled back to the liver [12]. This highly efficient process is called enterohepatic circulation 
(Figure 2) [25] and plays a vital role in liver function, metabolic regulation and liver physiology. 
Bile contains a complex mixture of endogenous bile salts, bilirubin, phospholipids, 
cholesterol, amino acids, steroids, enzymes, porphyrins, vitamins and heavy metals as well as 
exogenous xenobiotics and environmental toxins. Bile functions as a powerful detergent and 
facilitates lipid and nutrition absorption as well as cholesterol and toxic metabolite excretion 
[7]. Due to the amphiphilic characteristics of bile salts, their accumulation in the hepatocytes 
would cause cell membrane damage, impair liver function and lead to cholestasis and 
cirrhosis. The liver regulates cholesterol homeostasis by balancing de novo cholesterol and 
bile salt synthesis, dietary cholesterol uptake, biliary cholesterol excretion, and reverse 
cholesterol transport from peripheral tissues. 
There are two main pathways in which bile acids can be produced: 1.) the classic (also called 
the neutral) pathway [26] and 2.) the alternative (also called the acidic) pathway [27]. Most 
likely, other pathways are also present, but they are considered inconsequential to the bile 





Figure 2. De-novo synthesis of primary bile acids: chenodeoxycholic acid (CDCA) and cholic acid (CA). The classical 
pathway is displayed on the left and is localised in the hepatocyte. The alternative pathway is displayed on the 
right and starts in the brain and macrophage. The rate-limiting step in the classical pathway is displayed in red 
and is catalysed by Cyp7A1, while the green box indicates the enzyme responsible for the composition of the 
de-novo bile acid pool. While all pathways result in the synthesis of CA and CDCA, the exact steps are not always 
known and these are indicated as interrupted lines.  (Aldo-Keto Reductase Family 1 Member D1 (AKR1D1), Aldo-Keto 
Reductase Family 1 Member C4 (AKR1C4), Cytochrome P450 Family 27 Subfamily A Member 1 (Cyp27A1), BACS/VLCS, Alpha-








1.2.1 The classical and alternative pathways 
De novo synthesis of bile acids occurs in the classical and the alternative pathway at the same 
time. However, the classical pathway occurs in the hepatocytes and is also known as the 
neutral pathway because all the intermediates are neutral sterols. De novo synthesis of bile 
acids in the liver in the classical pathway accounts for ~90% of bile acids produced and occurs 
by converting cholesterol into bile acids by the action of cytochrome P450 enzymes (Figure 2, 
hepatocyte)  [28]. The first conversion is immediately the rate-limiting step. Cyp7A1 converts 
cholesterol into 7a-hydroxycholesterol which in turn is converted into 7a-hydroxy-4-
cholesten-3-one [29]. The pathway then splits into two separate routes, one leading to cholic 
acid (CA) (Figure 2 left side of the path) and the other to chenodeoxycholic acid (CDCA) (Figure 
2, right side of the path). The distinction is caused by Cyp8B1, which is responsible for the 
composition of the de-novo bile acid pool. Following on from here, the steps are identical 
again and are catalysed by the enzymes Aldo-Keto Reductase Family 1 Member D1 (AKR1D1), 
Aldo-Keto Reductase Family 1 Member C4 (AKR1C4), Cytochrome P450 Family 27 Subfamily 
A Member 1 (Cyp27A1), BACS/VLCS, Alpha-Methylacyl-CoA Racemase (AMACR), Acyl-CoA 
Oxidase 2 (BCOX), BDP, and SCPx. Following their synthesis, most bile acids are conjugated to 
taurine and glycine by Bile Acid-CoA:Amino Acid N-Acyltransferase (BAAT) [30]. 
The alternative pathways start in peripheral tissues, also called the acidic pathway as the 
intermediates tend to be acids and account for the remaining ~10 % de novo produced bile 
acids. The pathway is initiated by Cyp27A1 inside the macrophage (Figure 2, 
macrophage)[27]. Following the conversion of cholesterol by Cyp27A1, Cyp7B1 and 
HSD3B1/3B2 into 7a-hydroxy-3-oxo-4cholestenoic acid, the newly formed acid is transported 
into the hepatocyte where further conversion via the classical pathway continues into CA and 
CDCA. The second alternative pathway is initiated by Cyp46A1 in the brain where cholesterol 
is converted into cholesterol 24(S)-hydrocholesterol. This substrate, in turn, is modified by 






1.2.2 Recycling of the bile acids via the enterohepatic pathway (Figure 3) 
The bile salts are then secreted into the canaliculi and subsequently stored into the 
gallbladder as mixed micelles or immediately released into the duodenum as bile [7]. After 
each meal, the gallbladder contracts to release bile salts into the duodenum in the form of 
mixed micelles with phospholipids. In the duodenum, bile salts will act as detergents to 
solubilise lipids and lipid-soluble vitamins, thus aiding in their absorption by the intestines 
[31]. A small fraction of the bile acids are further converted by gut microbiota into secondary 
bile acids such as deoxycholic acid (DCA) and lithocholic acid (LCA) [32,33]. Recycling of bile 
salts from the gut is initiated by their uptake across the apical membrane of enterocytes by 
the sodium-dependent bile salt transporter (ASBT). Close to 95% of the bile acids, both 
primary and secondary bile acids, are reabsorbed through the intestinal wall, enter the 
enterohepatic circulation, and are transported back to the liver. However, lithocholic acid and 
sulphate conjugated bile acids are mostly excreted via urine [6]. After the bile acids have been 
transported back to the liver, hepatocytes reabsorb the bile acids across the basolateral 
membrane of the hepatocytes by organic anion transport protein 2 (OATP2) and the sodium-
taurocholate co-transporting polypeptide (NTCP, SLC10A1) [34]. In this way, bile salts can be 
secreted and re-adsorbed in more than 20 cycles before being excreted from the body via the 















Figure 3. Schematic depicting the enterohepatic pathway. CA = Cholic acid, CDCA = chenodeoxycholic acid, GCA 
= glycocholic acid, GCDCA = glyco-chenodeoxycholic acid, TCA = taurocholic acid, TCDCA = tauro-
chenodeoxycholic acid, DCA = deoxycholic acid, UDCA = Ursodeoxycholic acid, GDCA = glyco-deoxycholic acid, 
GUDCA = glyco-ursodeoxycholic acid, TDCA = tauro-deoxycholic acid and TUDCA = tauro- Ursodeoxycholic acid. 





1.3 Bile Salt Export pump  
The mammalian ABC transporter ABCB11 known as BSEP was first described by Nishida et al. 
in 1991 in the canalicular membrane vesicles of the rat liver [35]. Due to BSEP’s similarities 
with ABCB1, BSEP was initially named "Sister of P-glycoprotein" (sPGP). BSEP consists of 1321 
amino acids in humans and has a molecular weight of ~160 kDa. While the BSEP’s 3D protein 
structure remains to be determined, it is thought to be similar to that of ABCB1. It is predicted 
to have two membrane domains (MDs) each containing six transmembrane helices (TMHs), 
and two cytoplasmic nucleotide-binding domains (NBDs) that contain the Walker A, Walker B 
and ABC signature sequences for ATP binding and hydrolysis [31]. The two ATP molecules bind 
at the NBD:NBD interface in two non-equivalent ATP binding pockets of which only one 
pocket catalyses the hydrolysis of the bound nucleotide. BSEP is specifically expressed in the 
liver and as its name suggests is responsible for the transport of bile acids as a rate-limiting 
step in bile acid biogenesis. BSEP is predominantly present in cholesterol-rich rafts in the 
apical membrane of hepatocytes where it is one of the most abundant canalicular efflux 
transporters [5]. 
1.3.1 BSEP: its importance and regulation 
Bile acids function as powerful detergents and facilitate lipid and nutrition absorption as well 
as the absorption of cholesterol and toxic metabolite excretion [36]. Due to these detergent 
properties of bile salts, their accumulation in the hepatocytes will cause cell membrane 
damage, impair liver function and lead to cholestasis and cirrhosis. In recent years, interest in 
canicular BSEP has increased, given its importance in the biliary clearance of numerous bile 
acids. Focus has shifted to BSEP’s roles in several pathogenic phenotypes, including DILI. BSEP 
expression is tightly controlled, and drugs able to interfere at any level of bile acid synthesis 
and transport will have a significant effect on the hepatocyte’s ability to clear bile acids.  
BSEP transcription  
BSEP-mediated transport is regulated at three distinct levels, (i) BSEP gene transcription, (ii) 
protein trafficking and (iii) transport activity. BSEP transcription is regulated by two 
transcription factors [31,37]. The first is the nuclear hormone receptor FXR and the second its 
heterodimeric partner, RXR. Both also control the expression of several other liver 
transporters. Alterations in the expression of either FXF or RXR would be capable of altering 




in human, rat and mouse confirm that bile salts increase BSEP expression in primary human 
hepatocytes or HEPG2 cells by activating FXR. Several bile acids can directly bind to the FXR 
and RXR [38]. For example, FXR can be activated by CDCA>DCA>LCA>CA in a reducing order 
[39], where CDCA selectively activates FXR expression. In another example, LCA inhibits BSEP 
expression by down-regulating agonist-dependent BSEP expression by directly binding to FXR. 
Although CDCA is thought to be most potent in activating FXR, LCA was found to exhibit a 
higher binding affinity. LCA has recently also been identified as an agonist of PXR, which is a 
second bile acid receptor that plays an essential role in liver detoxification. However, PXR 
does not regulate BSEP gene expression. 
Intracellular trafficking of BSEP 
The second level at which BSEP is regulated is the continued recycling of the protein and its 
trafficking between intracellular endosomes and the canalicular membrane on the apical side 
of hepatocytes. This regulation is mediated by kinases and ubiquitination, and is based on 
several mechanisms [40] (see Figure 4). A reduction in the amount of BSEP at the membrane 
can be achieved by either increasing the recycling away from the apical membrane via hypoxia 
(through Ca2+-dependents, PKC mediated mechanism [41]) or via the activation IL6, IL1a and 
TNFα by Lipopolysaccharide (LPS). The transport from Rab 11-positive endosomes to the 
apical membrane can be disrupted by activation of phosphoinositide 3-kinase (PI3K)/protein 
kinase B pathway by estradiol-17b glucuronide and oxidative stress, in a Ca2+-dependent 
manner. This in turn activates the protein kinase C epsilon pathway in a Pi3K dependent 
manner, which in turn activates AKT pathway and prevents the movement of BSEP towards 
the membrane [42]. LCA, in turn, can directly activate the PKC pathway in a PI3K dependent 
way. To increase the amount of BSEP at the membrane, microtubule inhibitors block cyclic 
AMP dependent insertion BSEP in the membrane. One of the most important reasons for 
BSEP to move towards the membrane is the need to export bile acids due to high 
concentrations in the cell. Bile acids can do this either by directly recruiting BSEP to the 
membrane (in case of TCA) or by recruiting BSEP to the membrane indirectly by activating the 
p38 and PKC pathway (as is known for TUDCA) [31]. The activity of kinases is intricately tied 
to levels of oxidative stress in hepatocytes. Thus, any drug affecting oxidative stress can 





Figure 4. Mechanism of BSEP trafficking within the cell. BSEP is continually recycled between intracellular 
vesicles and the apical side of the hepatocyte. cAMP, P38/PKC and TCA directly increase BSEP incorporation into 
the membrane. Estradiol and oxidative stress both inhibit BSEP trafficking to the membrane via a Calcium 
dependent activation of Akt pathway, LCA inhibits the trafficking by activating he Pi3K pathway directly. While 
trafficking away is regulated directly by hypoxia and via IL6, Il1α and TNFα via LPS.  The green arrows indicate a 













1.3.2 Multiple causes exist for DILI  
Due to the recycling of bile acids and BSEP, events causing cholestasis and DILI may be divided 
in: i) prehepatic events, where the liver is inhibited from taking up unconjugated bilirubin, ii) 
intrahepatic events, where bile acids are prevented from leaving the liver and iii) post-hepatic 
events, where an injury of the bile duct prevents clearing of bile acids [43,44]. These effects 
can be caused by either direct or indirect effects of drugs (Figure 5). Drugs can have an indirect 
effect by altering the effect of nuclear hormone receptors (responsible for regulating gene 
transcription), bile acid synthesis or the regulation of BSEP protein expression at the 
membrane. Direct effects can consist of inhibiting the uptake of bile acids into the hepatocyte, 
effects on the bile acid pool, and the inhibition of bile acid export from the hepatocyte. It is 
the latter where BSEP is the rate-limiting step and the designated transporter [31]. Due to 
BSEPs importance in clearing bile acids from the hepatocyte, it is custom in pharmaceutical 
companies to investigate the effect of drugs on BSEP inhibition in a transport assay [45]. In 
this assay, inside-out membrane vesicles are incubated with radiolabelled TCA in the presence 
and absence of tested drug. After a defined incubation time the excess TCA is washed away, 
and the TCA accumulated within the membrane vesicles is measured (Figure 6) [35]. Many 
drugs causing idiosyncratic DILI have been shown to inhibit BSEP at relevant in-vivo steady-
state drug concentrations in plasma of humans. However, these assays do not report on the 
individual effects of drugs on specific bile acid concentrations. The potential indirect effects 






Figure 5. Overview of possible effects of drugs/compounds affecting bile acid concentrations or bile acid 
compositions within the hepatocyte.  
 
Figure 6. Schematic showing how the direct inhibition of BSEP activity is investigated by pharmaceutical 
companies. Inside-out Sf21 membrane vesicles are incubated with radiolabelled TCA in the presence of different 
concentrations of the drug. After a specified incubation time, the excess external radiolabelled TCA is washed 
away, and the radiolabelled TCA captured in the lumen of the membrane vesicles is measured. If the drug is a 





Alternative drug effects on BSEP’s efficiency to transport bile acids  
Finally, BSEP transport activity can be strongly influenced by drug-protein interactions. BSEP 
has been shown to interact with many different drugs when it comes to direct inhibition of 
transport activity. However, drugs can directly inhibit proteins in several other ways. Drugs 
could irreversible inhibit BSEP by binding covalently to the protein and changing or blocking 
its binding pockets. Alternatively, BSEP can be inhibited by reversible inhibitors by three 
different mechanisms: I.) competitive inhibition (Vmax constant, Km increased), where drugs 
directly compete with the substrate (i.e. bile acids) to be transported for binding in the 
binding pocket. II.) non-competitive inhibition (Vmax reduced, Km is constant), where drug 
binding to BSEP is independent of substrate binding, and where drug binding would prevent 
bile acid transport, and III.) uncompetitive inhibition (Vmax and Km reduced), where drugs 
would bind to the BSEP-substrate complex, and inhibit further progression of the transport 
reaction [47]. Type 1 inhibition could be overcome by an increasing the amount of substrate 
and would be more pronounced for bile acids that bind with reduced affinity to BSEP. This 
type of inhibition could therefore alter the composition and possibly the toxicity of the bile 
acid pool in hepatocytes [48]. As BSEP expression and functionality are crucial for liver 
protection, further studies on these mechanisms are therefore of utmost importance. 
1.3.3 BSEP mutations 
Due to the crucial role of BSEP in the excretion of bile acids, alterations in BSEP activity have 
a significant effect on the functioning of hepatocytes [49]. The effects can consist of alteration 
of liver regeneration, glucose homeostasis, energy expenditure, atherosclerosis or 
carcinogenesis. The effect may be ascribed to the detergent and hydrophobic aspects of bile 
acids that activate the apoptotic pathways. There are several liver diseases related to BSEP 
dysfunction [7]. BSEP mutations are able to cause several detrimental phenotypes in humans, 
the diseases associated with them are called PFIC2, benign recurrent intrahepatic cholestasis, 
type 2 (BRIC2), and intrahepatic cholestasis (IHC) of pregnancy.  
Many mutations responsible for impaired BSEP function have traditionally been linked to 
PFIC2 and BRIC2. However recent studies show that BSEP impairment or alteration can 
explain intrahepatic cholestasis in pregnancy, diabetes type 2, colon cancer, primary biliary 




Missense mutations can influence BSEPs ability to transport bile acids, affect protein stability 
and degradation and transport and incorporation to the membrane. All of these can influence 
not only the total bile acid accumulation but could possible cause a shift in internal bile acid 
composition towards more toxic bile acids.  
In a search of the literature, we were able to find 264 known point mutations in BSEP (Figure 
9 see Appendix A and B). However, many of them have only been reported in case studies 
where a patient showing symptoms of cholestasis has been screened for BSEP mutations. The 
effect of BSEP mutations on protein expression, protein function, or how these point 
mutations affect protein structure have often been neglected (see Figure 7).  
PFIC2  
Mutations in ABCB11 causing PFIC2 in the ABCB11 gene, and a typical feature is the absence 
or reduction of canicular BSEP expression [7,50]. There are many known missense or 
nonsense mutations associated with PFIC2 [51,52]. Nonsense mutations cause premature 
termination of translation, thus explaining the absence of BSEP expression. Missense 
mutations are generally thought to cause a deficiency of BSEP due to interference with 
splicing efficiency, or by inducing misfolding of BSEP protein and lastly by enhancing BSEP 
recycling due to changes in ubiquination patterns. Interestingly, almost all missense 
mutations within the transmembrane helices are associated with severe phenotypes of BSEP 
disease (PFIC-2, see Figure 8). 
BRIC2 
BRIC-2 is a milder form of liver cholestasis and can be caused by either heterozygous or 
homozygous mutations in the ABCB11 gene [53]. Recently the possibility of a transition 
between BRIC2 and PFIC2 was proposed in cases of homozygous G374S mutations [54]. 
Amino acid 374 is part of the sixth transmembrane helix of BSEP and lies in the vicinity of the 
translocation pore for the substrate, which would explain the reduced transport capacity. A 
common polymorphism p.V444A has been associated with an increased prevalence of DILI 
[34]. However, no kinetic difference has been found between WT and P.V44A mutation in TCA 
transport assays [55].  
While both diseases are caused by mutations in BSEP, they differ in their respective 




requires a liver transplantation to save the patient. BRIC2 is a more benign disease, 
characterised by intermittent episodes of cholestasis, which does not show progression. [16] 
When researching mutations associated with BSEP, D482G and E297G are the most common 
but there are many inconsistencies in literature dependent on the cell types and assay used 
to investigate them. Both are known to decrease taurocholic acid transport in Sf21 insect cells 
expressing BSEP. However, in HEK 293 cells these mutations revealed normal TC transport 
[53]. One observation is that mutations associated with PFIC2 are more dangerous to BSEP 
function than BRIC2 associated mutations. Little research has been done into this. Kagawa et 
al. 2007 showed that six mutations associated with PFIC2 were associated with reduced 
expression level at the membrane. This is in agreement with Ling et al. [17] who show that 
expression levels of BSEP at the apical site of the membrane are inversely associated with the 
severity of cholestasis.  
Intrahepatic cholestasis of pregnancy  
Another type of cholestasis associated with BSEP is ICP. This is a cholestatic disorder that 
usually develops in the third trimester of pregnancy and persists until delivery and affects 
about 1.5% of pregnancies among Caucasians. [18] 
Point mutations associated with known effect on protein
activity
unknown effect of mutations
effect of protein expression level
effect on protein function
 
Figure 7. Point mutations and their known influence. 264 total known point mutations, 32 known to affect 





BSEP mutations can have a devastating influence on BSEP functionality. A comprehensive 
literature review showed that 264 pointmutations are known in BSEP, of which only 32 are 
known to influence the BSEP expression and 36 affect protein activity. A graphical image 
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Figure 8. A count of mutations, where they occur compared to the disease they are associated with. The number 
of mutations associated with progressive familial intrahepatic cholestasis type 2 (PFIC2), benign recurrent 
intrahepatic cholestasis type 2 (BRIC2), intrahepatic cholestasis of pregnancy (ICP),  drug induced liver injury 
(DILI),  non-fibrosing cholestasis (NFC), mutations with no disease association, others, benign association, how 
many of these mutations are associated with more than one disease, and the total count. (location is based on 





Figure 9. Homology model created based on MDR1 crystal structure. Image A displays all the mutations that have been 
annotated in literature on top of the proposed structure for BSEP. Image C indicates the location of all mutations that are 
correlated to the respective diseases PFIC2 (red), BRIC2 (green) and IHC (yellow). Figures B and D are the respective of image 





1.4 Overview of chapters in this thesis 
The aim of this research was to increase our understanding of the bile salt export pump, how 
it transports bile acid and how dysfunction might cause DILI.  
For this we have addressed several hypotheses: 
1.) Compounds can inhibit the bile salt export pump in either competitive, non-competitive, 
uncompetitive or in a mixed competitive manner.  
2.) Compounds can affect the bile acid pool composition in addition to the total bile acid 
concentration.  
3.) Compounds can influence BSEP expression at the membrane and thereby affect the bile 
acid concentration and pool composition. 
 
Chapter 2 will give an overview of methods and procedures that were used in the various 
experiments. 
Chapter 3 will investigate the drug-based mechanisms of direct BSEP inhibition.  
Chapter 4 will give a general introduction into metabolomics that is relevant for the results in 
the next two chapters.  
Chapter 5 investigates the effect of drug treatments on the metabolomics of individual bile 
acids in 2D and 3D cultured primary human hepatocytes.  
Chapter 6 investigates the effect of treatments on the metabolomics of signalling lipids that 
play a role in inflammation or protective measures, and that are responsible for 
communicating effects to other cells. 
In Chapter 7, the conclusions and data from this research are discussed in the context of 
















2.1 Protein expression in Sf21 insect cells 
Human BSEP protein was expressed in Spodoptera frugiperda (Sf21) insect cells. Similar to 
human cells, insect cells offer the advantage that expressed proteins undergo post-
transcriptional modifications. However, insect cells present several advantages to 
mammalian cells, such as the ease of culture, the high tolerance to by-products and the 
generally higher protein expression levels.  
The steps involved in the expression of human proteins in insect cells are as follows:  
 
The Bac-to-Bac baculovirus expression system was chosen as the method for protein 
expression in Sf21 cells. The steps to go from the gene of interest to protein expression are 
explained in Figure 10. The donor plasmid, providing the gene of interest, used was pDEST8 
(Figure 11) which was transformed into competent E. coli cells containing a helper plasmid 
and the Bacmid DNA (Figure 12). The helper plasmids function is to assist in trans-positioning 
the gene of interest into the Bacmid vector. Following the transposition, the cells were 
selected with antibiotics, and Bacmid DNA was isolated. The Bacmid was then transfected 
into Sf21 cells to produce recombinant baculovirus that allowed me to obtain BSEP expression 
in Sf21 cells. 
2.1.1 
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Figure 10. Method of bac to Bac protein expression for Sf21 cells. Image obtained from Invitrogen life 
technologies [56]. 
 
2.1.1 Mutants and gene constructs used in the preparation of inside-out membrane vesicles 
containing BSEP  
To express BSEP in Sf21 cells, the following plasmids and primers were used. 
pDest8 construct  
pDEST 8 is a Gateway destination vector for expressing proteins in insect cells using the Bac-
to-Bac baculovirus system. The plasmid contains a polyhedron promotor and ampicillin and 
gentamycin resistance genes. The target Gene is inserted between attB1 and attB2 via 
recombination with attL flanked target gene. AstraZeneca supplied pDest8 vector containing 





Figure 11. pDEST8 including BSEP sequence. Obtained from Snapgene. 
pFastBSEP plasmid map 
The pFastBSEP plasmid is provided in competent E. coli DH10 cells with the following 
genotype: F-mcrA Δ (mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Δ lac X74 recA1 endA1 araD139 
Δ(ara, leu)7697 galU galK λ - rps L nupG/pMON14272. The plasmid contains a low-copy 
number mini-F replicon, a kanamycin resistance marker, and a segment coding for LacZa 
peptide from PUC plasmid into which the attachment site for the bacterial transposin Tn7 
(min-attTn7) has been inserted. While the insertion itself does not disrupt LacZα peptide, it 
can still complement a partial deletion in the bacterial DNA to express LACz peptide. In the 
presence of blue-gal of X-gal and the inducer IPTG, cells containing this bacmid will produce 
a blue dye and create blue colonies. The E. coli DH10 cells also contain the helper plasmid 
pMON7124 encoding the transposases which confers resistance to tetracycline. pMON7124 




Once the gene of interest has been inserted into the TN77L site, with the use of the helper 
plasmid pMON7124, the partial LacZ gene on the plasmid has been disrupted, and the 
colonies (with the correctly inserted gene of interest) are unable to produce blue colonies and 
will be white instead.  
 
Figure 12. pFastBac1 plasmid map displayed without ABCB11. Obtained from Snapgene. 
Genes, Sequences and primers  
Wild type (WT) of ABCB11 was achieved via round-the-horn mutation using the primers in 
Table 1. BSEP mutants indicated with an * in Table 2 were bought from GenScript. 








Table 2. Summary of mutants created and acquired via GenScript.  
Alternative 
names  
DNA changes Amino acid change/name  
WT c. 1517C>T A444V 
AZ mutant c.1517T>C V444A 
* c.1517C>T, c.1174T>A, c.1175G>C W330A 
* c.1517C>T, c.1195T>G, c.1196A>C Y337A 
* c.1517C>T, c.2500T>G, c.2501A>C Y772A 
* c. 1517C>T, c.3283A>G, c3284G>C R1033A 
* c. 1517C>T, c.3272A>G T1092A 
  
To confirm that the amplified DNA sequences only contained the desired mutation, the entire 
ABCB11 gene in pDest8 was sequenced using 10 forward and 1 reverse primer (indicated in 
Table 3) 
Table 3. Primers used for sequencing 

















2.1.2 Obtaining the ABCB11 c. 1517C>T gene with round-the-horn site-directed mutagenesis.  
To enable ligation of the amplified plasmid DNA after the round-the-horn mutagenesis, 
primers were first phosphorylated by the addition of 35 µL Milli-Q water, 5 µL polynucleotide 
kinase (PNK) buffer A (enclosed with PNK), 1µL 50 mM MgCl2, 1 µL 100 mM ATP, 1 µL 
polynucleotide 5'-hydroxyl-kinase (PNK) and 5 µL 100 µM primer together in sterile Eppendorf 
tubes. The mixture was then incubated for 30-60 min at 37C, and PNK was inactivated by 
heating the mixture to 65°C for 20 min. The primers were then mixed and stored at -20°C until 
use. 
The mutagenesis was performed by mixing 10 ng pDest8 containing ABCB11 c.1517T>C with 
35 µL MQ, 10 µL 5x GC buffer, 1 µL (10 mM) dNTP mixture, 5 µL of the combined 
phosphorylated primers, and 0.5 µL Phusion polymerase. The mutagenesis mix was 
immediately placed in thermocycler using the settings as specified in Table 4.  
Table 4. Thermocycler settings for RTH site-directed mutagenesis 
temperature time repeats 
Initial denaturation 98°C  60 s 1X  
Denaturation 96°C 30-60 s 
20-25X Annealing Tm -5°C  30-60 s 
Extension 72°C  30 s/kb (for Phusion)  
Final extension 72°C  5-10 min  1X 
Cooldown and idle 4°C 10 min - O/N optional 
 
The acquired product was digested with the restriction endonuclease DPN1 overnight at 37°C 
and subsequently run on an 0.5% agarose gel. After the appropriate band was excised, DNA 
was extracted using the Gel extraction kit (Thermo Fisher). Equal amounts of binding buffer 
were added to the gel, and the mixture was heated at 60°C for 10 min. The mixture was then 
filtered in supplied filter tubes for 1 min at 16000x g. The flow through was discarded and the 
filter was washed twice. DNA was eluted in sterile MQ and measured for yield and purity.  
The linear DNA was then ligated to create a vector with T4 DNA ligase for 1-2 hrs at 22°C and 
stopped by heat denaturation at 80-85°C for 5-10 min. Plasmids were then stored at -20°C 




2.1.3 Amplification of pDest8 plasmid in E. coli 
Plasmid isolation  
Plasmid pDest8 containing the ABCB11 gene was extracted from 10 mL overnight E. coli 
cultures using the GeneJET plasmid miniprep kit according to the manufacturer's instructions 
(Thermo Scientific). The cell pellet was resuspended in 250 µL resuspension buffer. The cells 
were lysed using the lysis buffer under inversion of the tubes. After the addition of 350 µL 
neutralisation buffer, the tubes were again carefully inverted. Separation of cell debris from 
plasmid DNA was achieved by centrifugation at 12800 x g (Eppendorf centrifuge) for 10 min. 
The supernatant was added to the included spin column and washed twice with wash buffer 
containing 70% ethanol, after which plasmid was eluted with 30 µL sterile-nuclease free 
water. Yield and purity of the plasmid preparations were checked using the nucleic acid 
setting on the NanoDrop 1000 spectrophotometer. The spectrophotometer calculates the 
absorbance of the sample at different wavelengths (range 220-350 nm) where the DNA 
concentration is based on absorbance at 260 nm. The purity is determined by two ratios: 
260/280 nm and 260/230 nm. The 260/280 nm should be around ~1.8; higher values indicate 
contamination with RNA and lower values indicate the presence of protein, phenol or other 
contaminants in the sample. The 230/260 nm ratio is a secondary purity analysis for nucleic 
acid and is in a good range between 1.8-2.2. Lower values in this ratio indicate the presence 
of co-purified contaminants.  
2.1.4 Transpositioning of DH10 Bacmid  
To transpose the ABCB11 gene from the pDEST8 to the Bacmid vector, 10 ng/µL pDest8 vector 
was added to DH10 Bacmid cells and incubated on ice for 30 min. The cells and plasmid 
mixture were heat-shocked at 42 °C for ~45 s. After an incubation on ice for 2 min, 200 µL 
SOC medium was added to each transformation and incubated at 37°C for 5-6 hours. To 
perform a blue/white screening the transformed cells were plated on L-agar plates (L-agar: 
37 g/L) with kanamycin (50 µg/mL), gentamicin (7 µg/mL), tetracycline (10 µg/mL), IPTG (40 
µg/mL) and X-gal (60 µg/mL). Plates were incubated at 37 °C for 48-72 hours. Before picking 
large white colonies, plates were stored at 2-8 °C for one hour, as this increased the difference 
between false and true positives. The Bacmid in the E. coli DH10 cells encodes LacZα peptide, 
which is able to produce a blue dye in the presence of X-gal and IPTG. Yet, once the gene of 




replaced after which the DH10 cells are unable to produce blue dye and therefore remain 
white. White colonies were picked for inoculated in L-broth containing kanamycin (50 µg/ml), 
gentamicin (7 µg/ml), and tetracycline (10 µg/ml) and placed overnight at 37 °C at 250 rpm. 
2.1.5 Plasmid isolation from E. coli DH10 cells 
Cell pellet obtained from the overnight incubation was frozen and thawed twice before being 
resuspended in P1 buffer from the Qiagen maxiprep kit and resuspended in P2 buffer. After 
4 min incubation P3 was added and carefully mixed. After spinning at 16000x g for 10 min at 
4 C. Supernatant was added to 800 µL propan-2-ol and incubated on ice for 10 min. After 
centrifuging for 16000x g for 15 min at 4°C the pellet was washed in 70% ethanol and 
centrifuged again at 16000x for 15 min at 4°C. After removing all ethanol, the pellet was dried 
for 2 min at RT, RNase free MQ was added to the pellet and pellet dissolved by a freeze-thaw 
cycle. Bacmid DNA was stored at -20°C till use. Extra care was taken to pipet the Bacmid as 
little as possible due to avoid DNA shearing due to its size.  
2.1.6 Sf21 Insect cell culture 
Sf21 cells were passaged in Sf900 II medium (Invitrogen) three times per week to ensure cells 
were maintained within the mid-log phase of growth. Cells were seeded at 3E+05 viable 
cells/mL (v.c./mL) in new vented shake flasks (corning) or roller bottles (corning) and grown 
for three days (Friday to Monday) and at 5E+05 v.c/mL for two days (Monday to Weds and 
Weds to Friday). Cells were incubated at 27°C at 140 rpm in the Innova (25mm orbit) 
incubator. Cells were checked for viability and diameter size on every passage. Cell cultures 









2.1.7 P1 Virus production  
The P1 virus stock is used as long-time storage and back-up to produce BSEP-containing 
membrane vesicles. If the volume falls below 1 ml, a long term P2 virus stock is to be 
produced. For each construct, 150 µL SF900II media (GIBCO), 20 µL Superfect transfection 
reagent (Qiagen) and 10 µL Bacmid DNA was added to selected wells and allowed to stand for 
30 min at RT. Cells were prepared at 5E+05 v.c./mL in SF900 II SFM +10% accredited fetal calf 
serum (FCS) and gentamicin (50 µg/ml) and added to the transfection mix. The mixture was 
then incubated at 27°C for seven days at 140 rpm in the Infors (3mm orbit) incubator. P1 was 
harvested by centrifugation at 3400 x g at 4°C for 10 min. P1 virus was stored at 4°C in light 
protected box. 
2.1.8 P2 production  
Long term virus prep 
This stock is necessary if the P1 virus stock would fall below 1 ml and can be used for long 
term storage. Sf21 cells at 1.5E+6 v.c./ml were seeded in SF900 SFM supplemented with 10% 
accredited fetal bovine serum (FBS). 1 mL stock virus was added per 500 mL cells in mid-log 
cells phase, after which the suspension was incubated for 7 days at 27 °C while shaking at 140 
rpm. The virus was aseptically harvested using sterile centrifuge tubes and centrifuged at 
3400 x g for 15 min at 4°C. Long term virus stock was stored at 4°C in a light-protected box.  
Short term virus prep 
A short-term virus prep always needs to be done before the infection of Sf21 to produce 
protein. To achieve a sufficient virus count, 1 mL P1 virus was added to 500 mL 1.5E+6 v.c./mL 
Sf21 and incubated for 2-3 days at 27 °C while shaking at 140 rpm. A sample was taken to 
check for infection, if cells were correctly infected with P1 virus the cell growth would be 
arrested, the cells would be swollen and the viability reduced. 25 ml of this preparation is 
directly added to 500 ml of prepared mid-log Sf21 cells to infect new cells for large scale 
protein expression (see section 2.1.9).  
2.1.9 Large scale protein expression  
The difference between when the Sf21 cells produce virus and when they are optimal for 
protein expression lies within the time of infection. Sf21 cells express the virus when the cells 




are still in mid-log (exponential phase) but are about to reach the stationary phase (see Figure 
13).  
Mid-log cells were grown until they reached a density between 2-5E+6 v.c./mL and directly 
infected with short term P1 virus (25 mL of the short term virus prep culture in 500 mL mid-
log grown cells). After 48 hrs of incubation the cell pellets were harvested by centrifugation 
at 3400 x g for 15 min at 4°C. Cell pellets were stored at -80 °C until further use.  
 
Figure 13. Growth curve of Sf21 cells with infection ranges for protein production and virus production indicated 








2.1.10 Virus titre evaluation  
A serial of dilution of 10E-1, 10E-2, 5E-3, 2.5 E-3, 1.25E-3, 0.625E-3, 3E-4 virus stock in SF900 
II SFM media was added to 2E+6 v.c./mL Sf21 at a 1:1 ratio. After 24 hrs of incubation, the 
cells were counted, and cell size was measured in Vi-CELL counter. [57] 
Probability that the Sf21 cells were infection was calculated according to the following 
formulas:  
𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛 =  
𝑐𝑒𝑙𝑙 𝑠𝑖𝑧𝑒[𝑇𝑥] − 𝑐𝑒𝑙𝑙 𝑠𝑖𝑧𝑒 [𝑇0]






= 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑜𝑓 𝑖𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑛 ∗ 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡 (𝑋1000)
∗ 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
The virus titer for each dilution was calculated and averaged to estimate the actual virus titer. 
 
2.1.11 Protein expression screening. 
A stock of Sf21 insect cells at 3E+6 v.c./mL was prepared in fresh SF900 II SFM media. 180 µL 
P1 or P2 baculovirus was added to 3 ml cells and incubated at 27°C for 48 hrs. The cell pellet 
was collected by centrifugation at 3400 x g for 10 minutes at 4 C. SDS-PAGE was used to detect 
and/or separate the protein using the detergent SDS. Samples containing equal amount of 
total membrane protein in 1X SDS sample loading dye (5x sample buffer: 2% SDS. 10% 
glycerol, 1% bromo-phenol blue, 62mM Tris-HCL (pH 6.8), 0.715 mM 𝛽-mercaptoethanol) and 
were separated on 10 % resolving/separating gel (pH 8.8) and 5% stacking gel (pH 6.8) 
(geneflow). A pre-stained protein marker was also loaded to identify protein size. The gel was 
run in 1x SDS buffer (25mM Tris base, 150mM glycine and 0.1% SDS, pH 8.3) at 15mA for 15-
20 min and then increased to 25 mA until the bromophenol blue reached the end of the gel.  
2.1.12 Membrane vesicle production  
Cell pellets were thawed on ice. Ultracentrifuge tubes were pre-chilled at 4 °C before use. 
Pellets were resuspended in hypotonic membrane vesicle buffer (0.5 mM Tris/HEPES, pH 7.4, 




suspension through the French press twice at 1.0 pounds per square inch (PSI), the solution 
was centrifuged at 1000xg for 10 min at 4°C. The supernatant was then centrifuged at 
72000xg for 60 min at 4°C (Beckman ultracentrifuge). The pellets were combined and 
resuspended in SMS buffer (10 mM Tris/HEPES, pH 7.4, 50 mM sucrose and protease inhibitor 





2.2 Biochemical assays using ISOVs containing BSEP  
2.2.1 BSEP-mediated bile acid transport 
BSEP mediated transport is measured in inside out membrane vesicles (ISOV) containing 
functional BSEP. These ISOVs can take up bile acids into the lumen. By using radioactive 
labelled bile acids, the transported bile acids inside the vesicles can be measured after 
washing away the excess external bile acids over a filter (see Figure 14). By changing the 
composition of the external buffer, the effect of drugs and other substrates can be 
characterized. 
 
Figure 14. Schematic of BSEP mediated bile acid transport in ISOVs. To detect inhibition of BSEP, bile acid 
transport is measured in inside out Sf21 membrane vesicles. The membrane vesicles are incubated with 
radiolabelled TCA in the presence of nucleotides and different concentrations of the tested drug. After a 
specified incubation time, the excess radiolabelled TCA is washed away, and the radiolabelled TCA captured 
inside the vesicles measured. If the drug is a weak inhibitor the radioactive signal will be larger than if the drug 










 IC50 determination for taurocholate transport 
Test compounds where serially 1 in 3 diluted from 1000 µM to 4.1 µM in DMSO. Compounds 
where inbacuted for at least 10 min at 37°C in Uptake buffer (final concentration: 10 mM 
HEPES/Tris pH7.4, 100 mM KNO3, 50 mM Sucrose and 12.5 mM Mg(NO3)2, 0.5 µM [3H]-
taurocholate + 0.5 µM cold-taurocholate, and 12.5 mM ATP or AMP). Membrane vesicles 
were then added to a final concentration of 0.5 g/ml. Following incubation for 5 min, samples 
were added to a filter plate containing Stop buffer (50 mM sucrose, 100 mM KCl, 10 mM 
HEPES/Tris pH 7.4, 0.1 mM taurocholate, 5 mM EDTA pH7.4), and subsequently filtered and 
washed twice with Stop buffer. After drying the plate overnight, MicroScint -20 (Perkin Elmer) 
was added, followed by incubation in the dark for 1 h. The plate was read in MicroBeta2 
scintillation counter (Topcount instrument) for 2 min per well.  
2.2.2 ATPase assay  
The ATPase activity of BSEP was measured in ISOVs in the presence or absence of ortho-
vanadate, different bile acid substrates and inhibitors, using the colourimetric malachite 
green assay. The malachite green assay measures the release of ortho-phosphate (Pi) due to 
BSEPs ability to hydrolyse ATP into ADP+Pi in the presence of a substrate. Malachite green 
forms a complex with Pi (Figure 15), the absorbance of which can be measured at 600nm.  
 
Figure 15. Example of malachite green’s colourimetric reaction with increasing concentrations of Pi. 
ATPase activity was measured using the malachite green assay to assess the production of Pi 
over time. Membrane vesicles were diluted to a final concentration of 0.05 mM protein in 30 
µL uptake buffer (Section 2.2.1) in the presence or absence of 10 mM ortho-vanadate. After 
preheating the samples for 10 min at 37°C, the reaction was started by the addition of 2.5 
mM Na-ATP (Thermo Fisher Scientific) after which Pi was released. Subsequently, the reaction 




freshly prepared malachite green-ammonium molybdate freshly activated by 0.1% Triton X-
100. The stopped reaction was then allowed to incubate at RT for 5 min before being stopped 
by the addition of 30 µL 34% citric acid after which OD600 was determined. The activity of 




2.3 Primary human hepatocytes 
Primary human hepatocytes (PHH) are harvested from donors and therefore considered 
physiologically more relevant than the easier to acquire cell lines HepG2 and HepaRG cells. 
Extensive research has been done on the difference between these cell lines and it has been 
concluded that PHH express Cyp450 enzymes at the same or near physiological levels making 
them exceptionally valuable to investigate bile acid synthesis and metabolism [58]. However 
little to no investigation has been done on what effect of 2D and 3D culturing has on toxicity 
response and metabolism. It was therefore decided to use both culturing methods to describe 
DILI compound effects on bile acid pools and BSEP function. In the following sections, the 2D 
sandwich culture and 3D spheroid culture methods are described in more detail (see Figure 
16). 
 
Figure 16. The difference between 2D culture and 3D culture. 
 
2.3.1 Primary human hepatocyte culture  
Primary human hepatocytes (AZ bioreclamation) were thawed at 37 °C and poured into 50 
mL pre-warmed KLC-TM media (Williams E media (Gibco), 3.3% cocktail A (10000 U/mL, 
Penicillin, 10000 ug/mL streptomycin, 4 mg/mL human recombinant Insulin, 200 mM 
GlutaMAX, 1M Hepes PH 7.4), 4.6% FBS, 0.009% dexamethasone). The mixture was then 
centrifuged at 170x g for 20 min at RT. All but 2-3 ml of supernatant was discarded and 
resuspended in the supernatant. After gently adding 25 mL pre-warmed thawing media 
(Williams E media, 3.3% cocktail A, 4.6% FBS, 0.009% Dexamethasone (Sigma)). To increase 
the viability of the cells, the cells were centrifuged at 100 x g and resuspended in 2-3 mL 
supernatant while the rest of the supernatant was discarded. The cell count and viability were 
determined using a 1:1 dilution of trypan blue and counting white (live) cells in a counting 




cells are still able to transport trypan blue out of the cell while dead cells will appear as solid 
blue dots due to their inability to transport trypan blue. Cell were then plated a density of 
7200 v.c./well. The cells were left to adhere for 6 hrs at 37°C, 5% CO2.  
Production of 2D sandwich culture 
To produce a 2D sandwich culture, Corning Matrigel was used to separate two different types 
of media by a layer of PHH (Figure 16). Due to the presence of the different media on each 
side of the cell, the cells can become as polarised as they would in physiological 
circumstances. Corning Matrigel (Corning) was diluted to 0.25 mg/mL in ice-cold basement 
Media (Williams E media containing 3.85% cocktail B and 9.6E-4% dexamethasone). After the 
cells were checked for adherence, plating media was removed, and 100 µL/well ice-cold 
Matrigel was added.  
Dosing and harvesting of 2D sandwich culture 
Dosing occurred 24 hrs after the cells were first plated in 100 µL InSphero tox proprietary 
media (phenol red was omitted as it interferes in the ultra performance liquid 
chromotography-MS/MS analysis of the samples). The plates were returned to the incubator 
till harvest for 6, 24 or 72 hrs. At the point of harvest, media was collected in individual 
Eppendorf tubes and immediately placed for storage at -80°C.  
Cells were washed 3X with cold dulbecco’s phosphate-buffered saline (DPBS). After DPBS was 
removed, 50 µL ice-cold methanol was added to fixate and dehydrate the cells. The samples 
were immediately stored at -80°C to prevent degradation of samples. 
3D cell culture  
3D spheroids were either obtained from InSphero or produced in-house by myself.  
Inhouse production of Spheroids: 
Primary human hepatocytes were obtained as described in 2.3.1 spheroid cells and 
resuspended in Williams E plating media containing: 10% HyClone FBS (ThermoFisher), 1% L-
glutamine-Penicillin-Streptomycin (Sigma), 1% insulin-Transferring- Selenium (life 
technology), and 0.1% Dexamethasone (Sigma).  The cells were plated in a low adhesive 96 
well Spheroid plate, at a density of 1500 cells/well. Cells were not seeded in the outer wells 




centrifuged at 125 x g for 2 min and then placed at 37°C. After 5 days a partial media change 
was performed by removing 50 µL media from the wells and adding 50 µL FBS free media. 
Seven days after plating the spheroids were ready for dosing.  
Dosing and harvesting of Spheroids:  
Dosing of InSphero spheroids was done 24 hrs after receiving the spheroids. Spheroids were 
allowed to settle back to the bottom of the plate for 5 min before the media being removed, 
after washing three times with InSphero tox proprietary media, 70 µL dosing media was 
added per well. The plates were returned to the incubator at 37°C for required for 6, 24 or 72 
hrs dosing time.  
After 6, 24 or 72 hrs of incubation, media was collected in individual Eppendorf tubes and 
immediately placed for storage at -80°C to prevent degradation of samples.  
Cells were washed 3X with cold DPBS, DPBS was removed leaving 10 µL liquid and the 
spheroid in the base of the well, then 50 µL ice-cold methanol was added. Both methanol and 
spheroid were transferred to individual Eppendorf tubes and immediately placed on dry ice 
and stored at -80°C.  
2.3.3 Metabolomic analyses 
The metabolomic analyses were carried out at the Biomedical Metabolomics Facility in Leiden 
by Dr A.C. Harms, Dr Alida Kindt-Dunjko and Prof Dr Thomas Hankemeier. Samples obtained 
from the 2D and 3D experiments were shipped on dry ice to maintain reliability of the 
measurement and were confirmed to be immediately placed at -80°C after the delivery of the 
samples at Leiden. For the 3D cells and media samples derived from this, two samples were 
pooled at Leiden prior to metabolomics analysis. For the 2D cells and media, no samples 
needed to be pooled. Cell samples and media samples were analysed in a randomised order 







Bile acids  
Table 5. Internal standards used in the bile acids profiling platform. d4 abbreviation indicates the amount of 
hydrogen isotopes within the different bile acids have been replaced with deuterium to detect the 











Each sample was spiked with an internal standard solution (Table 5) of 1 mM final 
concentration. The extraction of bile acids compounds is performed by protein precipitation 
with methanol, after collection, the supernatant is concentrated by first drying and then 
reconstituted in a smaller volume, after reconstitution, the extract is transferred into amber 





Signalling and peroxidised lipids 
Table 6. Internal standards used in the signalling and peroxidised lipids profiling platform. the d-number 
abbreviation indicates the amount of hydrogen isotopes that have been replaced with deuterium to detect the 
corresponding molecule. 




d4-linoleoyl ethanolamide  
d4- dehydroepiandrosterone-2,2,3,4,4,6 
d8- anandamide 
d4- Palmitoyl Ethanolamide 
d8-N-arachidonoyldopamine 
d4- Oleoyl Ethanolamide 
d3- Stearoyl Ethanolamide 
d4- thromboxane B2 
d5-Tauro-ursodeoxycholic acid 





d4-8iso-11-deoxy-13,14-dihydro-15-keto-11β,16.xi.-cycloprostaglandin E2  
d4-11-deoxy-13,14-dihydro-15-keto-11β,16.xi.-cycloprostaglandin E2  






d4- Leukotriene B4 
d4-(±)12,13-dihydroxy-9Z-octadecenoic acid  




d6- 20-hydroxy Arachidonic Acid 
d4-(±)-9-hydroxy-10E,12Z-octadecadienoic acid  
d8-12(S)- hydroxy Arachidonic Acid 
d4-Lithocholic acid 







Each sample was spiked with antioxidant and internal standard solutions (Table 6). The 
extraction of the compounds was performed via liquid-liquid extraction. Depending on the 
preference of the solute, they will either remain in the aqueous phase or move to the organic 
phase. To extract the signalling lipids from the aqueous phase, butanol and ethyl acetate were 
used. After collection, the organic phase is concentrated by first drying and then 
reconstitution in a smaller volume of the organic phase. After reconstitution, the extract is 
transferred into amber autosampler vials and used for low pH injection. 
Equipment  
A Shimadzu system formed by three high-pressure pumps (LC-30AD), controller (CBM-
20Alite), autosampler (SIL-30AC) and an oven (CTO-30A) from Shimadzu Benelux was coupled 
online with a LCMS-8050 triple quadrupole mass spectrometer (Shimadzu) operated using 
LabSolutions data acquisition software (Version 5.89, Shimadzu). The samples were analysed 
by UPLC-MS/MS using an Acquity UPLC HSS T3 column (Waters). The triple quadrupole mass 
spectrometer was used in polarity switching mode, and all analytes were monitored in 
dynamic Multiple Reaction Monitoring. All metabolites were detected in negative mode. 
Data Analysis 
The acquired peak data was evaluated using LabSolutions software (Version 5.89, Shimadzu), 
by integration of assigned MRM peaks and normalisation using accordingly selected internal 
standards. When available, a deuterated version of the target compound was used as internal 
standard. 
2.3.4 The interpretation of data by multivariate analyses  
Multivariate analysis is a statistical approach to assess data with more than one variable and 
thus more than one statistical outcome variable at a time. Multivariate analysis is useful to 
reduce a large number of variables and identify clusters.  
In this case, it was decided to use multivariate analysis for this data due to the high number 
of y-variables (12 different bile acids) and five different x-variables (2D vs 3D; cell vs media; 
treatment and time). While several options for modelling are possible, an unbiased PCA-X 
modelling (see next section) was chosen. The interpretation of multivariate analysis needs to 
































Figure 17. Workflow used to obtain multivariate graphs in SIMCA. (workflow created with: ©2019 





PCA-X model fitted over data: To uncover groupings of variables, trends and outliers, the data 
were fitted to principal component analysis-X (PCA-X) model. PCA-X uses an orthological 
transformation to reduce the dimensionality of large data sets. It achieves this by changing a 
large set of variables into a smaller set, without losing information, into new variables called 
components. Graphs were assessed for their R2, and Q2 values, both of which needed to be 
above 0 and components were added till neither R2 or Q2 further increased. The R2 values 
the percent of variation explained by the model and therefore relates to how well the model 
fits the data. A poor R2 indicates a poor reproducibility in the data set. The Q2 value is the 
percent of the variation of the data set predicted by the model after cross-validation and 
therefore indicates how well the model predicts new data. A large Q2 (>0.5) indicates a good 
predictivity.  
Scores plot: A score scatter plot was created if the model was deemed to be adequate and 
give a sufficient fit. In this new graph, t1 and t2 are newly generated variables summarising 
all univariate results of the samples at once. Each score is independent of the others, and 
there are as many scores as there are components in the data. Score t1 explains the largest 
variation, t2 the second largest and so on. Accordingly, the scatter plot allows us to look at 
how each sample is situated with respect to each other. Allowing us to see outliers, groups, 
similarities and other patterns in the data. In Figure 18, an example of a scores scatter plot of 
t1 and t2 is shown. Four different groups are clearly separated and can therefore easily be 
identified in the graph. The ellipse indicates the Hotelling’s bases T2, indicating the 95% 
confidence interval. Observations located outside of this ellipse are outliers that cannot be 
explained by the model. A manual check of outliers was done before exclusion. If no reason 
for the outlier was found, the outlier was left in the data set. Samples close to the origin of 





Figure 18. An example of the score scatter plot with four different groups indicated by different colours. T1 
explains the largest variation while T2 explains the second largest variation. In this example groups can be 
identified by clear separation, indicated by different colours.  The individual samples within the groups share 
commonalities among them. The ellipse indicates the Hotelling’s bases T2, indicating the 95% confidence 
interval.  
 
Loading plot: a loading scatter plot was created to evaluate which variables had the most 
influence on the placement of the individual samples. The scores are weighted averages of 
the variables with p1 in the first component and p2 in the second component. These values 
express the correlation structure of the x matrix and show how the X-variables correlate to 
each other. There are two distinct ways this pot is read and used. I) an imaginary line is drawn 
through the origin, allowing for the interpretation of the X-variables. Variables near each 
other are positively correlated see Variable 4 and 2 in Figure 18. Variables opposite to each 
other are negatively correlated, see Samples 4 and 3 (Figure 18). By drawing a line from the 
sample through the x-axis we can identify uncorrelated samples. Samples located at a 90-
degrees angle from this imaginary line are uncorrelated to each other in these two 
components, such as the 4 and 1. The further these points lie from the origin, the stronger 
the impact that variable has on the model. Showing that Variable 4 and 2 are responsible for 
the separation of the blue group in Figure 19, variable 5 is responsible for the separation of 






Figure 19. Loading scatter plot in which each number represents a different X-variable. The loading plot 
correlates and can directly be overlaid with the score scatter plot, indicating which group is associated with 
which variable. Variables that are located close to each other are positively correlated see examples 4 and 2. 
Variables that are located at a 90-degree angle are uncorrelated see 4 and 1 as well as 5 and 3. Variables that 













2.3.5 ATP (viability) measurement  
CellTiter-Glo 3D Reagent (Promega) was thawed overnight at 4°C before use. CellTiter-Glo 3D 
reagent was equilibrated at RT for approximately 30 min. 100 µL CellTiter-Glo 3D Reagent was 
added to wells containing 100 µL media and live cells. After thorough mixing, the suspension 
was transferred into a black 96-well plate and mixed on an orbital well shaker for 5 min to 
induce cell lysis. Plates were spun at 300 x g for 2 min to remove bubbles. After 25 min 
incubation at RT, plates were luminescence read on the Envision using an integration time 
0.25-1 second/well.  
Values were verified against a standard curve prepared with adenosine 5′-triphosphate (ATP) 
disodium salt hydrate in nuclease-free water. 
2.3.6 Total bile acid concentration  
Total bile acid concentration within cells was measured with the cell Biolabs “total bile acid 
kit” (cell Biolabs MET-5005). The principle of the analysis is explained in Figure 20. Bile acids 
are oxidised with the use of 3α-hydroxysteroid dehydrogenase. In the reaction, the enzyme 
reduces NAD+ to NADH. NADH, in turn, is used by the enzyme diaphorase to reduce non-
fluorescent resazurin to fluorescent resorufin. After allowing this reaction to take place for an 
hour the resorufin concentration in the samples is determined spectrophotometrically in a 
plate reader at excitation and emission wavelengths of 560 and 590 nm, respectively.  
 
Figure 20. Biochemical mechanisms underlying the total bile acid assay. Bile acids are oxidised via 3α-
hydroxysteroid dehydrogenase (HSD) in a step that also reduces NAD + to NADH, this in turn enables diaphorase 





Absolute concentrations of all bile acids combined were obtained by generating a standard 
curve for glycochenodeoxycholic acid with concentrations ranging from 0 to 25 µM. Stock 
solutions of 250 µM were provided as a standard in MQ water in the kit. Media from both 2D 
and 3D cell cultures were harvested and stored in Eppendorf tubes, after which the cells were 
washed three times with cold DPBS. For the 2D cultured cells, 50 µl DPBS was added to the 
plates and both media and plates were stored at -80°C till further use. The spheroids were 
washed three times and were transferred to Eppendorf tubes. Before the total bile acids 
assay, the spheroids were centrifuged at 10.000xg for 10 min and resuspended in 50 µL media 
to ensure similar dilutions for each of the samples. The media and the cells were stored at -
80°C before analysis. On the day of total bile acid concentration analysis, the cells were 
thawed and refrozen twice before sonication to ensure lysis of the cells. 50 µL of each sample 
was analysed according to the kit instructions. To prevent interference of fluorescent signal 
from neighbouring wells the entire assay was performed in black-walled plates.  
2.3.7 Staining and imaging  
Cells were washed to remove media and fixed at a final concentration of 4% 
paraformaldehyde in DPBS to retain protein structures, in a final volume of at least 100 µL at 
RT for 1 h in a biological safety cabinet class 2 and stored at 4 °C until staining.  
Antibodies used for imaging of both 2D and 3D cultures:  
Primary antibody  Mouse anti-BSEP (F-6) sc 74500 (SantaCruz) 
Secondary antibody  Goat anti-mouse IgG (H+L) fluor 488 (thermoFisher A28175) 
Nucleus stain  Hoechst 33342 (thermoFisher) 







2D cells were fixed to the plate as stated in 2.3.7 and permeabilised at RT for 15 min with 0.1 
% Triton X-100 and 0.2% BSA in PBS to allow the antibodies to enter the cells. After blocking 
with 2% BSA for 1 h, primary antibody in PBS containing 1% BSA was diluted 1:100 at RT for 1 
h. After washing with cold PBS, the secondary antibody was applied with a dilution of 1:500 
together with Hoechst (1µgmL), HCS cell mask and 1 % BSA. After 45 min incubation, samples 
were washed with PBS and imaged with Yokogawa CV8000.  
3D cells 
Incubation with primary antibody was changed to 18-24 hrs at 37 °C and secondary antibody 
for 4 hours at 37 °C. Each washing steps was 20 min each to allow for diffusion of antibodies 
into the microtissue [59]. 
2.3.8 Image analysis  
Images analysis was done on web enabled image analysis platform Columbus (PerkinElmer).  





Figure 21. Workflow for analysing the z-stack images in Columbus (PerkinElmer). Z-stacks were loaded into the 
program where after the Hoechst channel was used to identify and count the number of nuclei. This nuclei count 
together with the cell mask channel was used to identify the outlines and the correct number of cells within 
each image. The membrane region was identified by identifying an area of interest 2.5% away from cell outline 
identified in step 3, the rest was names cytoplasm region. Finally, the objects in the BSEP signal channel were 
counted and defined by total object count/cell, object in membrane region/ cell and objects in cytoplasm 
region/cell.  
1. Load images
2. Use the hoechst channel to Identify nuclei
3. Use the CellMask channel to identify the 
outlines of cells 
4. Define the membrane region 
5. Define the cytoplasm region
6. Count total objects/cell, objects in membrane region, 





2.4 Statistical analysis  
Two-way ANOVA followed by Tukey’s multiple comparisons test was performed using 
GraphPad Prism version 8.0.1 for Windows, GraphPad Software, San Diego, California USA, 
www.graphpad.com 
Significance is displayed as:  
Ns P > 0.05 
* P ≤ 0.05 
** P ≤ 0.01 
*** P ≤ 0.001 










3.1 Introduction  
3.1.1 Different bile acids 
The current limitations in providing an assay that can predict DILI may be explained by the 
wide variation in the compounds that can interfere with BSEP expression or transport activity. 
It might, therefore, be prudent to look at compound interactions beyond the direct inhibition. 
A few considerations need to be made such as the bile acid pool, which can influence bile salt 
accumulation in many complex and dynamic ways. While primary bile acids are synthesized 
in the hepatocytes, they can undergo enzyme-catalysed conjugation with taurine and glycine 
into amidated bile acids. The mixture is then actively transported out of the hepatocytes by 
BSEP. Along the small intestines, bile acids may be reabsorbed by the apical sodium-
dependent bile salt transporter (ASBT) and the basolateral organic solute transporter (OST) 
[31,60,61]. In the gut the bile salt may undergo further metabolism by bacteria into secondary 
bile acids. It is therefore unsurprising that each tissue has its bile salt signature profile, 
providing different compositions of bile salts in each organ [43,62]. These signatures are 
dependent on absorption, distribution, metabolism and excretion rates. Each bile salt has an 
individual uptake rate. For example, there have been confirmed reports of a ~30 fold 
difference in the uptake rate of specific bile acids by BSEP [43].  
3.1.2 Kinetics of transport activity and inhibition. 
Membrane transporters are enzymes that mediate the transmembrane movement of their 
substrates, often without modifying them. Although the traditional Michealis-Menten model 
was developed to investigate enzyme kinetics, it can also be used to describe the kinetics of 
drug transporters in terms of Km, Ki, and Vmax [63], which the Km describes the affinity of 
the drug for the transporter, the Ki defines the affinity for the inhibitor, and the Vmax 
describes the maximum velocity of substrate transport. Nowadays computer calculations are 
accurate enough to perform non-linear curve fitting of data to determine the Vmax and Km 
parameters. However, in the past the hyperbolic Michaelis-Menten graph was transformed 
into Lineweaver-Burke and/or Eadie-Hofstee plots, which are both linear graphs. In the 
Lineweaver-Burk plot the x-intersection= -1/Km and y-intersection= 1/Vmax. However due to 
the transformation process samples with small substrate concentrations, the most prone for 




is less prone to variations and the y intersection=Vmax and the slope=-Km. These linearization 
methods still provide amazing tools to visualise inhibition types (see Figure 23) 
 
Figure 22. Identification chart for types of inhibition. Includes Michealis-Menten, Lineweaver-Burke and Eadie-











3.1.3 Types of inhibition  
Reversible inhibition can be divided into four groups, competitive, non-competitive, 
uncompetitive and mixed competitive.  
1.) In competitive inhibition the inhibitor competes with the substrate for the same binding 
at the active site. The Vmax does not change in this instance but the Km increases. The 
inhibitor can be competed of by increasing the substrate concentration [64].  
2.) In non-competitive inhibition the inhibitor binds to a different site than the substrate but 
in the process alters the shape of the transporter or enzyme, it cannot be overcome with 
increasing the substrate concentration. In this case the Vmax and the Km decrease with the 
addition of an inhibitor [64].  
3.) In the case of uncompetitive inhibition, the inhibitor binds to the substrate-transporter 
complex. An uncompetitive inhibitor causes the Vmax to decrease but the Km to remain the 
same. As the substrate increases so does the complex and thus inhibition, it does therefore 
not compete off [64].  
4.) In mixed inhibition, the inhibitor can bind to the transporters regardless if a substrate is 
already bound or not although it has a greater affinity for one state or the other. It is in 
essence a mix between competitive and uncompetitive inhibition. In the case of a mixed 
inhibitor the substrate affinity may decrease if the inhibitor prefers the free enzyme or the 
Km may increase if the inhibitor prefers to bind to the substrate-transporter complex. In both 
cases the Vmax will decrease however [64].  











3.2.1 Compounds selection  
Before the start of experiments, four compounds were carefully selected to study the 
consequences of drug interactions in hBSEP. The selection criteria were established before 
the selection of these four compounds and consisted of: 1. The known inhibitory effect on 
hBSEP, 2. Have one compound well defined in enzyme kinetics and mechanistic properties 3. 
Causing different types of DILI injuries. Figure 23 displays the most common hBSEP inhibitors 
colour coded and then organised according to their physio-chemical properties.  
As bosentan has a very low affinity for BSEP but can induce DILI, the inhibition by this positive 
control was chosen as a cut-off point by AstraZeneca in the analysis of new compounds. 
Compounds with a weaker affinity than bosentan are not clinically relevant in inducing DILI. 
All of these properties are used for drug efficiency screening before testing. The ClogP, for 
example, is a well-established measure of the compound's hydrophilicity. A high 
hydrophilicity (or low hydrophobicity) and therefore low logP value is associated with poor 
absorption or permeation. The polar surface area is regularly used to optimise the ability of 
drugs to permeate cells. It is a common view that a higher polar surface area results in poorer 
permeation through the cell membrane. The heavy atom count (which refers to the presence 
of electronegative atoms such as O, N and S) is commonly inversely related to ligand 
efficiency. The ligand efficiency describes the measurement of the binding energy per atom 
of a ligand to its binding partners, such as a receptor or enzyme. This is commonly used in 
drug discovery research programs to assist in narrowing focus to lead compounds with 
optimal combinations of physicochemical properties and pharmacological properties [65]. 
Rotatable bonds, h-bond donors and h-bond acceptors are often used to define the 
compounds solubility and oral bioavailability. By using these properties drug developers are 
able to discriminate out inactive compounds before further screening. 
Before the final selection of the compounds, the physico-chemical properties were plotted 
against the IC50 value for BSEP inhibition. In Figure 23, compounds were sorted from high to 
low IC50, indicating a low inhibitory effect on BSEP activity to a high inhibitory effect, and were 
given their unique colour in a colour gradient. Subsequently, the compounds were sorted 
according to other physico-chemical properties from high to low and colour-marked them 





Figure 23. Compounds sorted by different chemical properties. Compounds were given a colour to differentiate 
them from each other and were sorted from low IC50 to high IC50 . For other criteria (molecular weight, ClogP, 
polar-surface area, heavy atom count, rotatable bond, h-bond donor, H-bond acceptors), the compounds were 
sorted from high value to low value. No obvious relationships could be detected between IC50 and the other 
criteria. 
 
Four compounds from the previous list of BSEP inhibitory agents tested by AZ were selected 
for further studies. As a known BSEP inhibitor, bosentan was included as a positive control. It 
has a molecular weight of 551.614 and an IC50 of 38.1 μM as determined by AZ (see Figure 24 
for additional information and chemical structure). The second compound chosen was 
alpidem with a molecular weight of 404.333 and an IC50 of 9.2 μM. The third compound was 
clobetasol propionate with a molecular weight of 466.97 and an IC50 of 8.5 μM. The last 
compound chosen was cyclosporine A with a molecular weight of 1202.611 and an IC50 of 0.5 
μM. For both bosentan and cyclosporine it was established previously that they inhibit BSEP-




Selection of these four compounds enables us to investigate the link between IC50, the 
mechanisms of inhibition, and the mechanisms underlying different DILI injuries. 
As Chapter 4 and 5 will report on the metabolomics and the influence of drugs on the location, 
two more compounds were included. Cyclohexamide is an inhibitor of protein translation, 
induced microtubule- and p38(MAP kinase-dependent decrease of Golgi-associated BSEP, 
accompanied by a more than 2-Fold increase in BSEP-positive pseudocanaliculi [42]. 
According to previous tests at AZ, cycloheximide is not known to inhibit BSEP directly in ISOVs 
(see Appendix C for hepatic panel score compounds from AZ). The second compound that 
was added was estradiol. Estradiol is a naturally occurring steroid hormone responsible for 
female reproduction, maintenance of body temperature, preserving bone strength, 
cholesterol production and protection of the heart [67]. Some foods may affect levels of 
estradiol in the body, and a synthetic form is often prescribed as a birth control measure and 
in the treatment of menopausal symptoms. Experiments in rats have indicated a reduction of 
BSEP at the apical membrane of hepatocytes in response to exposure to this compound [68]. 
AZ has shown that estradiol is a direct weak inhibitor of BSEP with an IC50 of 111 µM (data 













3.2.2 Effect of compounds on taurocholate (TCA) transport 
hBSEP was expressed in Sf21 insect cells and inside-out membrane vesicles were prepared. 
The effects of bosentan, clobetasol propionate, cyclosporine A, alpidem and estradiol on the 
BSEP-mediated TCA uptake in these membrane vesicles is shown in Figure 2. All compounds 
were found to inhibit TCA transport by BSEP, however the estradiol data did not lend itself to 
a fitting. The least inhibitory compound was estradiol with an IC50 of 437.4 μM and the most 
inhibitory cyclosporine with an IC50 of 0.42 μM. Bosentan, clobetasol and alpidem had IC50 of 
63.2 μM, 6.44 μM and 3.9 μM, respectively. It is interesting to note that while bosentan 
exhibits a 150x higher IC50 than cyclosporine, both cause cholestatic/mixed DILI. Clobetasol 
propionate was found to inhibit TCA transport stronger than bosentan but is commonly found 
not to cause any DILI. These results suggest that the IC50 in a TCA transport assay plays a minor 
role in defining what type of liver damage a compound can cause. It should be noted that TCA 
is not the most abundant bile salt in human liver and that the possibility exists that the 
inhibition of BSEP by inhibitors could be bile ion-dependent. The next step was identifying the 
























































































































Figure 24. Determination of IC50 for inhibition of BSEP-mediated TCA transport by various drugs in the presence 
of 0.5 µM cold-TCA and 0.5 µM [3H]-TCA, uptake was stopped after 5 min of incubation and samples measure 
the next day. Graphs were plotted as sigmoidal, 4pl plots were the x is log(concentration) (N=3). Estradiol data 







Table 7. Summary of IC50 values for inhibition of BSEP-mediated taurocholate transport. * IC50 was determined 
but the curve did not lend itself to fitting a curve.  
Compound   IC50 (µM) 
Bosentan 63.2 





The analysis of ATP-dependent TCA uptake in hBSEP-containing membrane vesicles served 
two purposes: i) To confirm that the BSEP assay was properly performed, and ii) to confirm 
that IC50 values observed for chosen compounds were in the correct range. The findings are 
within the confidence interval described by Dawson et al [16]. 
Kinetics of TCA transport 
Having identified inhibitors of BSEP, the next aim was to study the biochemical mechanisms 
(competitive vs non-competitive vs uncompetitive inhibition) by which the inhibitors block 
BSEP activity. For this purpose, a transport assay was established in which the rate of BSEP-
mediated transport was measured as a function of the TCA concentration. 
In Figure 25, TCA uptake at increasing TCA concentrations is displayed over 900 seconds. The 
hyperbolic substrate accumulation curves show that linear uptake occurred between 
approximately 20 to 180 s. A plot of the initial rate of uptake (Figure 26) versus the TCA 
concentration revealed a Vmax of 169 pmol/s/mg protein and a Km of 46.45 µM (Table 8, 
Figure 28). The data were also plotted in linear Lineweaver-Burk and Eadie-Hofstee plots. 
To determine the mechanism of inhibition, the TCA transport assays were repeated in the 
presence of inhibitors at concentrations equal to their IC50 and ½ IC50 in the uptake assays in 
Figure 24. As the IC50 for estradiol was very high, and its primary influence on BSEP is exerted 
at the level of expression rather than activity, it was excluded from further kinetic studies. 











































Figure 25. Taurocholate transport over time with different TCA concentrations with DMSO as control. one site 
binding hyperbolas were fitted onto the data indicating a Ki and Vmax for each concentration of TCA (N=3). 



































Figure 26. The linear sections in Figure 7 were used to evaluate the initial velocity of TCA uptake at different TCA 
concentrations. Linear regression were plotted onto the first 140 seconds from figure 25. To determine the 





















































































































































































































































Figure 27. Determination of uptake rates at different concentrations of inhibitor (in µM). Linear regression were 
plotted onto the first 220 seconds to determine the individual rates of TCA uptake by BSEP. The colour coding 

























































































































































































































































































































Figure 28 Michaelis-Menten graphs (A, D, G, J), Lineweaver-Burke plots (B, E, H, K) and Eadie-Hofstee plots(C, F, 
I, L) for TCA transport with 1/2* IC50 determined in Figure 6 (blue), IC50 (red) and DMSO (black).  A non-linear 
regression was used to identify the Vmax, and Km in the Michaelis-Menten, while a linear regression was used 
in the Lineweaver-Burke plot, a segmented line was used to identify the initial linear part in the Eadie-Hofstee 








From the graphs, we can deduce that according to the Lineweaver-Burke plot all compounds 
cause competitive inhibition of BSEP-mediated TCA uptake. However, it was more difficult to 
directly fit the data to an Eadie-Hofstee plot as it frequently shows a biphasic relationship 
between the rate and the rate/[TCA]. The high-affinity component (with significant negative 
slope) represents BSEP-mediated transport, whereas the low-affinity component (with very 
shallow slope) represent time-dependent low-capacity binding of TCA to the lipid bilayer in 
the membrane vesicles. Analysis of the high-affinity component suggests that bosentan, 
cyclosporin A, and clobetasol propionate act as competitive inhibitors (Vmax is constant, Km 
increases) or non-competitive inhibitors (Vmax decreases, Km is constant). On the other hand, 
alpidem appears to act as an uncompetitive inhibitor. However, in most cases, this analysis is 
based only on the assays containing inhibitors at a concentration that causes 50% inhibition 
(IC50).  
 
Table 8 Summary of kinetic parameters of TCA transport in Sf21 membrane vesicles. Assays were performed, of 
which one representative data set is shown in Fig. 1 and 3. ½ IC50 dose and IC50 dose refer to low dose and high 
dose, respectively. (No compound n=3 and compounds n=1) 
  


















DMSO   169 46.45 22.5 4.6 125.9 34 
bosentan 
1/2 IC50  ~ 3.161E15 ~ 4.061E15 -32.6 -62.4 6.1 11.2 
 IC50  88.41 38.41 -62.5 -33.4 87.13 40.66 
cyclosporine 
A 
1/2 IC50  330 213 -15.0 -17.7 30.42 36.13 
 IC50  67.76 18.38 
242.2 73.0 184.5 88.91 
clobetasol 
propionate 
1/2 IC50  85.39 37.57 82.1 30.2 94.25 45.03 
 IC50  110.8 41.79 
38.6 10.9 115.2 44.31 
alpidem 
1/2 IC50  163.6 71.42 -35.9 -23.0 -27.92 29.57 





The non-linear regression analysis of the Michaelis-Menten appears to be most reliable; it 
should be noted however that the ½[IC50] showed substantial confidence intervals. In the 
Lineweaver-Burk plot, the slope of the line is affected the most by the lowest TCA 
concentration that give high numbers for the reciprocal. Given the low transport rates at low 
concentrations of TCA, these high data points are the most inaccurate.  
3.2.3 Effect of compounds on glycocholate (GCA) transport 
There are over 20 bile acids in the human body that are transported continuously by BSEP. 
However, when it comes to purchasing radiolabelled bile acids, there is only one other bile 
acid (glycocholic acid, GCA) available in addition to the TCA. GCA is a glyco-conjugated form 
of CA, which is more abundant in the body than TCA. It was therefore vital to investigate the 
transport kinetics of BSEP-mediated GCA transport. This endeavour gave us a new challenge 
as detection of this bile acid from background was difficult. After several experiments, excess 
amounts of Mg2+ in the buffer appeared to be a major issue in this assay. 
3.2.4 The effect of magnesium on GCA transport 
 Mg2+ is necessary for the proper hydrolysation of ATP by the nucleotide binding domain of 
BSEP, however in the BSEP inhibition essay and additional 12.5 mM Mg2+ is added in the 
reaction buffer on top of the 0.1 mM Mg2+ in the ATP solution. Figure 29 displays the effects 
of Mg2+ on the transport of TCA and GCA in the presences and absences of ATP. Magnesium 
is essential to the proper working of ATP hydrolysis by ABC transporters, and in TCA transport 
excess amounts of Mg2+ appeared to be beneficial for the transport reaction in the presence 
of 5 mM ATP. However, for GCA we see that excess of 12.5 mM Mg2+ inhibits the ATP-









Effect of excess Mg2+ on TCA and GCA transport





































Figure 29 The effect of excess magnesium on BSEPs ability to transport TCA and GCA in the V444A mutant. 
Disintigrations per minute (DPM) is in direct relation to the accumulation of radio-labelled TCA and GCA. The 
results indicate that magnesium interferes with BSEP V444A’s ability to transport GCA however TCA 



























Inhibition of MgSO4 on BSEP V444A
 
Figure 30. Effect of MgSO4 on BSEP-mediated GCA transport. Increasing concentrations of MgS04 interfere 
directly with BSEP V444A’s ability to transport [14C]- GCA, with an IC50 217.8 µM. interestingly transport was 
maximally inhibited by 50%. Graphs were plotted as sigmoidal, 4pl plots were the x is log(concentration) (N=3) 
 
To establish the IC50 for inhibition of BSEP-mediated GCA transport by Mg2+, MgSO4 was 
included in the transport assay (see Figure 30). The results indicate an inhibition of the 
transport reaction with an IC50 of 217.8 µM. Interestingly, transport was maximally inhibited 
by 50%. Hence, part of the transport activity was found to be independent of the excess Mg2+. 
GCA contains a carboxyl-containing glycine moiety whereas TCA contains a sulfonic acid 
moiety; these acidic groups might have different interactions with Mg2+. To investigate if Mg2+ 
binds directly to GCA and TCA, Mag-fluo-4 was used to measure the amount of free Mg2+ in 
the presence of increasing amount of bile acids (see Figure 31). Measurements of the Mag-
fluo fluorescence emission showed that GCA shows a similar trend as EDTA, and hence, that 
GCA removes free Mg2+ from the solution through binding. In contrast, the Mag-fluo 
fluorescence emission was relatively unaffected at increasing concentrations of TCA. The 
complexation of GCA by Mg2+ may affect the concentration of free GCA that is available for 
transport by BSEP; it also possible the GCA and Mg-GCA are both transported by BSEP but 
with different rates and/or affinities. Furthermore, Mg-GCA formation might cause 
dissociation of GCA from the membrane in which the free bile acid will partition. In the line 




cytosolic population of bile acids with different rates and/or affinities. In an attempt to 
measure the effects of Mg2+ on bile acid binding to a membrane surface, the Mag-fluo-4 assay 
was repeated in the presence of liposomes. However, the results showed that liposomes were 




























Figure 31. Mag-fluo-4 fluorescence measurements with backgrounds subtracted (only MgSO4 and substrates).  
Second order polynomial (quadratic) non-linear regressions were fitted on top of the data to indicate the 
different responses between the individual substrates.  
 
 IC50 evaluation of selected compounds on GCA transport by BSEP 
In further transport assays, the inhibition of BSEP-mediated GCA transport by the selected 
compounds was measured (Figure 32). The results suggest that only bosentan caused 
inhibition at a very low concentration, whereas clobetasol propionate, cyclosporin A and 
alpidem shows no inhibition up to a concentration of 1000 µM. While the SD values for 
bosentan were acceptable, the standard deviation for the other compounds were very large. 
Repeats of the measurement did not change this. In spite of this, the data suggest that the 
























































































































Figure 32 Inhibition of BSEP-mediated GCA transport by selected compounds. Graphs were plotted as sigmoidal, 




3.3 Discussion of the results 
The data and analyses in this chapter confirm that there is no clear correlation between the 
physicochemical or functional properties of compounds and their ability to inhibit BSEP. This 
finding is in line with the fact that physicochemical are currently unable to predict which 
compound will cause DILI, and with the conclusion that DILI occurs in an idiosyncratic way. 
[16].  
For TCA transport by BSEP, we found a Vmax of 169 pmol/min/mg protein and a Km of 46.5 
µM, with previous literature stating the Vmax around 250 pmol/mg protein/min with a Km of 
4.1 µM [69] and another stating the Vmax of 4290 pmol/min/mg protein and a Km of 4.6 µM 
[70]. Although our measurements yielded a lower affinity for BSEP-mediated TCA transport 
than reported in the literature, these values are all in the lower µM range. Consistent with 
this the IC50 values were in agreement with those stated in the literature [15,71].  
The kinetics of BSEP-mediated TCA transport was determined in the presence of the inhibitors 
to study the biochemical mechanisms of inhibition. Our Lineweaver-Burk analyses points to a 
competitive mechanism for the tested compounds. Regarding these compounds, there are 
conflicting reports in the literature where one study suggests competitive mechanisms [72] 
whereas another proposes an uncompetitive mechanism for cyclosporine A [73]. The latter 
study also found that the impact of competitive vs non-competitive BSEP inhibition is of vital 
importance, as non-competitive inhibitors led to a much more significant bile acid 
accumulation in the liver and increased potential toxicity. According to the data in this work, 
the Eadie-Hofstee plots indicate that bosentan, clobetasol propionate and cyclosporin A act 
as competitive or non-competitive inhibitors. Alpidem on the other hand shows 
uncompetitive behaviour in the Eadie-Hofstee plot. This difference in inhibition types is very 
interesting and could explain in part why alpidem, although it has roughly the same IC50 as 
clobetasol propionate, causes liver injury whereas clobetasol propionate does not.  
While our kinetic data regarding TCA transport by BSEP shows a possible explanation 
regarding the toxicity of BSEP beyond simple IC50 determination, it is essential to note that 
kinetic analyses are not generally done within pharmaceutical industries. At present, most 
pharmaceutical companies rely on a panel of tests that include BSEP IC50 determination with 




compounds proceed to the next stage of testing and development. A recent review does not 
take into account how the type of inhibition can have different outcomes in drug toxicity [74].  
Another factor that affects drug toxicity is the prevailing bile acid concentration and 
composition. In our study, we found significant differences for the inhibition of TCA and GCA 
transport. This is consistent with published research on the effect of compounds on BSEP-
mediated TCA and GCA transport. Although for some compounds little difference was found 
for the IC50 of inhibition, other compounds including acitretin (IC50 29.27 µM for TCA and 100 
µM for GCA) and troglitazone (TCA: 1.98 µM, GCA 15.96 µM) yielded significant differences 
[71]. Hence, it is vital to consider which bile acids are important to investigate. GCA has 
previously been shown to be a stronger BSEP substrate in humans while TCA is stronger in 
rats [75]. However, while there is data available, we cannot compare our data with the 
published date due to the variability in the amount of Mg2+ in assay buffers in the published 
studies. As we have shown in this chapter, excess free Mg2+ has a significant inhibitory effect 
on BSEP-dependent GCA transport. This novel finding requires further investigation. Mg2+ is 
the fourth most abundant cation in the body and plays an essential physiological role in 
physiology [76]. Some of the primary functions of Mg2+ in human biology include the 
maintenance of ionic gradients (keeping intracellular sodium and calcium low and potassium 
high), cellular and tissue integrity, mitochondrial oxidative phosphorylation (ATP production 
and activation), and DNA, RNA and protein synthesis and integrity [76]. Chronic diseases, 
medications and magnesium decreases in food crops well as the availability of refined and 
processed foods, causes that the vast majority of people in modern societies are at risk for 
magnesium deficiencies. Given our finding on the complexation of GCA and Mg2+, the free 
bile acid concentration might be different in individuals with sufficient or deficient Mg2+ 
levels, and this might relate to the incidence of idiosyncratic Drug induced liver injury (iDILI). 
In line with this, Mg2+ has been shown to have a protective effect on bile duct ligation and 
















4. The effect of BSEP membrane 
expression on total bile concentration 





4.1 Introduction  
Chapter 3 concluded that BSEP has different preferences in the transporting the different bile 
acids, to investigate this in more detail chapter 5 will look at the influence of compound on 
bile acid metabolomics. However, in primary human hepatocytes, drugs can have effect on 
more than just BSEP. Compounds can cause toxicity and influence cell survivability, and they 
can affect BSEP expression and localisation. However, hepatocytes are also able to take up 
bile acids in an OATP and NTCP-dependent manner, allowing us to see the effect on bile acid 
recycling and total bile acid concentration. In this chapter we will introduce the cells prior to 
looking into the bile acid signalling lipid metabolomics (chapter 5 and 6 respectively).  
4.1.1 Donor information  
To investigate the effect of DILI inducing drugs on BSEP regulation, BSEP trafficking and bile 
acid pool composition, experiments were developed in collaboration with AZ and the 
University of Leiden to explore the effects of iDILI inducing drugs in greater detail. To this end 
bile acids were measured in two types of cell culture, the first being sandwich cultured (2D) 
PHH and the second being spheroid cultured (3D) PHH. The donors were close in age, had 
similar causes of death, and were both Caucasian. However, the donor used for the 2D cell 
cultures was female while the donor for 3D was male (see Table 9).  










 2D sandwich 3D Spheroids Donor 3 
Gender female male female 
Age 78 68 27 
Race Caucasian Caucasian African American 
Cause of death 
cerebrovascular 
accident 
Cerebral anoxia anoxia 
Smoker yes no None reported 
Alcohol usage yes yes None reported 
Alcohol history occasional occasional None reported 




4.1.2 Selection of test compounds 
Chapter 3 looked at the effect of compounds on BSEP directly (Table 10). However, in primary 
human hepatocytes drugs can have other effects too, the cell cultures were therefore 
exposed to one of four different compounds chosen for their different effects on BSEP 
(displayed in Figure 33): i) Bosentan is a dual endothelin receptor antagonist, affecting both 
endothelin A and B receptors, which prevents the narrowing of blood vessels and is used to 
treat hypertension. Bosentan was chosen as a test compound because the drug is known to 
inhibit BSEP and is used by AstraZeneca as a positive control in their BSEP inhibition panel. It 
can cause severe hepatic side effects in some patients [66]. ii) Clobetasol propionate is a 
derivative of prednisolone that exhibits a high glucocorticoid activity and is used as a topical 
treatment for psoriasis. Clobetasol propionate was chosen as a test compounds because 
while the drug is known to inhibit BSEP no hepatic side effects are known [45]. iii) 
Cyclohexamide is a naturally occurring fungicide produced by Streptomyces griseus and that 
is an inhibitor of protein translocation. The precise mechanism of action has yet to be fully 
understood however it has been shown to inhibit translation elongation through binding to 
the E-site of the 60S ribosomal unit and interfering with the deacetylated tRNA [79]. However, 
Kubitz et al. 2004 indicate that cycloheximide increases BSEP expression at the apical 
membrane of the hepatocyte in a microtubule and p38 map kinase dependent manner, which 
is why it was chosen as a test compounds for this study. iv) Estradiol is a naturally occurring 
steroid hormone responsible for female reproduction, maintenance of body temperature, 
preserving bone strength, cholesterol production and protection of the heart [67]. Some 
foods may affect levels of estradiol in the body, and a synthetic form is often prescribed as a 
birth control measure and in the treatment of menopausal symptoms. Estradiol was chosen 
because experiments in rats have indicated a reduction of BSEP at the apical membrane of 
hepatocytes in response to exposure to this compound [68]. The effect of estradiol on human 
liver, however, is age-dependent rather than gender-specific [80].  
The cells were harvested at 6 hrs for early assessment, 24 hrs for intermediate and 72 hrs for 






Figure 33. Image depicting the predicted effects of drug exposure. BSEP is recycled continuously within the 
hepatocyte with a vast amount stored within vesicles in the cytoplasm for fast recruitment to the apical 
membrane. Bosentan and clobetasol propionate have direct effects on BSEP activity, while cycloheximide is 
known to increase BSEP expression at the membrane in the first hours. Estradiol is known to cause a decrease 
of BSEP expression in rats. 
A summary of information regarding drugs used so far and is displayed in Table 10.  
 
Table 10. Summary of the drugs used in chapter 4, 5 and 6. Data was obtained from AZ database (not published)  
 
 IC50  
(µM) 
Type of damage  Comments 
Cyclosporine A 0.57  cholestatic/mixed 
 
Bosentan 44.16 cholestatic/mixed 
 
Alpidem 2.64 hepatocellular 
 
Clobetasol propionate 7.74 none 
 
Estradiol >1000 *unknown in humans improves liver damage in rats 











4.2.1 Cell survivability in response to treatments is affected by cell donor.  
ATP levels were measured as an indication of how cell survivability was affected by the 
different treatments. In Figure 34A and B the ATP levels of the 2D and 3D cultures are 
displayed. The effect of treatment on 2D cells indicated significant effects of the different 
treatments at 72 hrs, while in 3D culture only cycloheximide appeared to be significantly toxic 
after 72 hrs of incubation. These results might suggest that primary human hepatocytes are 
better protected against toxicity when cultured in 3D. To exclude the effect of donor 
variability the experiment was repeated with a third donor, (Figure 35). Figure 35, however, 
indicates that cells in both 2D and 3D cultures experience significant toxicity in response to 
dosing. It can therefore not be concluded that 3D cells are better able to cope with the effects 
of toxicity in response to different treatments. The effect may be donor-specific or gender-






















































































































































Figure 34. Cell survival of 2D and 3D cultured hepatocytes at 72 hrs. These are the same cells as used and 

























































































































Figure 35. Cell survival of 2D and 3D cultured hepatocytes at 6, 24 and 72 hrs. Primary human hepatocytes were 
obtained from Donor 3.  * indicates comparison with DMSO control, # compares identical treatments with 
previous time point.  (N=3) 
 
4.2.2 The bile acid concentration is not directly related to the position of BSEP in 2D cell cultures. 
To investigate the effect of treatments on BSEP distribution in the primary human 
hepatocytes, the cultures were harvested and stained with anti-ABCB11  for BSEP protein, 
Hoechst 33342 for nuclei, and CellMask for the cytoplasm (for representative images see 
Figure 37,Figure 38, and Figure 39 ). The analysis of staining was done by using Columbus 
image analysis program, which contains the following steps:  
Step 1: Hoechst staining was used to identify the nucleus and identify the number of cells.  
Step 2: CellMask staining was used as cytoplasm staining to identify regions of interest, i.e. 
individual cells. 
Step 3: the Columbus program was then able to calculate regions of interests separately, such 
as cell membranes and cytoplasm.  
Step 4: Anti-ABCB11 staining was used to identify the location of BSEP in either the cell 
membrane or the cytoplasm.  
Step 5: Objects, indicating BSEP, were counted per cell, and averages per cells are displayed 




To investigate the effect of treatments on bile acid displacement and production, the total 
bile acid concentration was measured in PHH and the media. Figure 36 displays the results 
obtained from the 2D PHH cultures. After 6 hrs of treatment (Figure 36A), significantly less 
BSEP in the cell was found in PHH treated with cycloheximide and estradiol. There is also 
significantly less BSEP in the cytoplasm of PHH treated with cycloheximide and estradiol. 
However, the cytoplasm of 2D cultured PHH treated with clobetasol propionates showed a 
significant increase in BSEP expression. In the membrane where BSEP performs its function 
of effluxing bile acids, only cells treated with estradiol showed a significant decrease in BSEP 
expression. This decrease, however, does not translate to the incorporation of BSEP into the 
membrane of cycloheximide treated cells. For cells treated with estradiol however 
significantly less BSEP was found in the membrane. 
Interestingly, the concentrations of total bile acid did not reflect the significant changes in 
BSEP location. After 6 hrs of treatment a significantly increased concentration of bile acids 
was only detected in PHH treated with estradiol in the media (Figure 36B). In cycloheximide 
treated cells, the only change was a significant decrease of total bile acid concentration inside 
the cell. 
At 24 hrs, a significant increase in BSEP expression in the whole cell can be seen in PHH treated 
with cycloheximide and bosentan (Figure 36C). In the cytoplasm we see a significant increase 
in BSEP in cycloheximide and bosentan treated cells, but no significant changes were detected 
in the membrane for any of the treatments. The analysis of the bile acid concentrations 
showed that no significant changes occurred in the media concentration, but that a significant 
decrease in bile acid concentration could be detected inside the cell for all treatments. 
However, this is due to the fact many of the cells probably lysed due to cell death detected in 
the ATP measurement (Figure 35A). 
At 72 hrs (Figure 36E), a significant general decrease of BSEP expression in PHH treated was 
observed with cycloheximide and estradiol. In the cytoplasm, a significant decrease is seen in 
cells treated with cycloheximide and estradiol, which in this case is also seen in the expression 
of BSEP in the membrane. In Figure 36F we see a significant increase in total bile acid 




significantly different due to the absence of viable cells at the point of harvest. It was, 
therefore, impossible to detect total bile acid concentrations in these cells.  
From these results, we can conclude that BSEP expression in the membrane does not 
correlate with the concentration of total bile acid in the cell or the media in 2D cultured PHH 




































































































































































































Figure 36. BSEP distribution and bile acid distribution in 2D cultures of primary human hepatocytes obtained 





Figure 37 Representative images of 2D cultured PHH harvested at 6 hrs and stained with Anti-ABCB11 (green), 
CellMask (red), nucleus (Blue).  Scale bar: 20 mm 
  





Figure 39 Representative images of 2D cultured PHH harvested at 72 hrs. Scale bar: 20 mm 
 
4.2.3 The effect of treatment on BSEP localisation and bile acid concentration in the 3D cultures 
The effect of treatments on BSEP localisation was investigated in the same way for 3D 
cultured PHH as the 2D cultured cells and results are displayed in Figure 40. However, several 
problems occurred during the analysis. 3D cultured spheroids appear to be too unstable to 
transfer to the imaging plate. There was an increasing number of missing samples at 24 hrs 
and 72 hrs. There were no significant differences detected at 6hrs in the expression of BSEP 
in the cell, cytoplasm or membrane of treated 3D cultured PHH. The analysis of total bile acid 
concentration in media and cells indicated a significantly higher concentration of estradiol 
treated PHH at 6, 24 and 72 hrs, but none of the other samples showed a significant change. 
It is possible that this result is caused by the low the detection limit could be that the range 
of detection of total bile acid concentration is caused by the low total bile acid concentration 
the detection of which is at the limits of what can be achieved in the assay. The experiment 
should, therefore, be repeated with samples where several spheroids have been pooled 
together. Pooling, however, does not increase the sensitivity of detection in media samples. 
























































































































































































Figure 40. BSEP distribution and total bile acid concentration in 3D cultured PHH obtained from Donor 3.  (N=3 





Figure 41. Fluorescently stained images representing 3D cultured PHH at 6 hrs. Scale bar: 50 mm 
 





Figure 43. Fluorescently stained images representing 3D cultured PHH at 72 hrs. Images for estradiol were 














4.3 Discussion of the results.  
3D cultured PHH have previously been shown to have relatively regular Cyp450 enzyme 
expression compared to human, and it is therefore expected that these cells have a more 
comparable drug metabolism than 2D cultured cells. This chapter investigated the effects of 
2D and 3D cultured PHH in the absence and presence of drugs that are known to either inhibit 
BSEP directly or change BSEP expression. From the viability assay we can conclude that the 
effect of treatments on viability is either donor-dependent or gender-dependent. It has 
previously been stated that there are donor-dependent responses to pharmaceuticals in 
human hepatocyte cultures. It is, therefore, necessary to analyse cells from multiple donors 
to obtain reliable results that can be translated to the entire human population [81]. It is, 
however, essential to note that pharmacokinetics in 3D cultured cells is more reliable than 2D 
cultured cells due to the near-normal expression of Cyp450 enzymes and critical proteins [18]. 
Six laboratories have previously shown that 3D cultured spheroids are more sensitive to 
hepatotoxic compounds and particularly in long term exposures [20]. This study considered 
inter-donor variability as well as laboratory variability. The 2D systems showed a more 
predefined differentiated phenotype and lower sensitivity to toxicity. Takayama et al., 2014 
showed that differences in hepatic metabolism are mainly due to genetic polymorphisms in 
its genes and that these polymorphisms have a significant influence on efficacy and adverse 
reactions to drugs [82]. These findings are all in line with the viability results for the cells. To 
fully understand the effect of 2D vs 3D on liver toxicity the experiment should be performed 
with different donors to include the effect of inter donor gene variations. Another way to 
evaluate the effect to a broader extent is to investigate polymorphisms in genes responsible, 
such as Cyp450. However, this would not test for genetic polymorphism in genes responsible 
for transport proteins such as ABCB11.  
The second part of this chapter looked at the expression of BSEP in PHH cultured in 2D and 
3D settings, as well as total bile acid concentration. Very little research has been done to 
investigate the effect of different treatments on BSEP expression. Often literature infers qPCR 
levels to an increase in BSEP expression in cells [83]. However, increases in gene expression 
do not necessarily relate to an increased expression of the functional protein [84]. A second 
way of looking at BSEP expression is by western blotting [85,86]. Since BSEP is continually 




fluorescence, therefore, offers a new and improved method to look at treatment effects on 
BSEP expression. From the results, we can conclude that BSEP expression if indeed is affected 
by different treatments does not necessarily correlate to the amount of bile acid being 
transported. 
Previous research using BSEP specific staining and quantification at the membrane has shown 
that a decreased amount of BSEP at the membrane is related to increased severity of PFIC2 
and BRIC2 [87]. The results indicate that while BSEP can significantly change upon different 
treatments this does not necessarily relate to increased concentrations of BSEP. Estradiol has 
previously been shown to significantly decrease BSEP expression [88]. This is in line with our 
findings at 6 and 72 hrs for 2D cultured cells. However, we were unable to replicate the effect 
in 3D 6 hrs where the effect was not significant. The second compound that affects BSEP 
expression is cyclohexamide. In previous studies, cycloheximide decreased the amount of 
BSEP in the Golgi apparatus caused a 2-fold increase of BSEP at pseudo-canaliculi in HepG2 
cells after 6 hrs of incubation [40]. After the initial increase of BSEP at the pseudo-canaliculi 
the number of BSEP positive canaliculi declined again until they reached normal levels at 16 
hrs. In the PHH 2D cultured cells we saw a significant decrease at 6 hrs in the whole cells and 
the cytoplasm, however at 24 hrs cycloheximide treated cells showed a significant increase in 
BSEP expression in the whole cell and the cytoplasm, but that did not translate to expression 
of BSEP in the membrane. At 72 hrs we see a significant decrease of BSEP in all compartments 
of the cell. The differences between the literature and the results in this thesis can be 
explained by the differences in cell lines as well as different culturing methods. The previous 
study used simple 2D culturing while this study used 2D sandwich culture.  
Several problems were encountered during the staining of the 3D spheroids. The first issue 
was the difficulty of transferring the spheroids from the culturing plates to the viewing plates. 
The second was that the loss of spheroids that were severely affected by toxicity and lost their 
integrity. A third problem was that antibodies required a longer time to sufficiently penetrate 
the entire spheroid [59]. We were able to get a full set to analyse the 6 hrs treated samples, 
but we were unable to get enough samples at 24 and 72 hrs. We can therefore not draw any 
conclusion from the staining data of the spheroids beyond the fact that it needs further 
optimising. Both the 2D and the 3D cultures, however, indicate a novel way to investigate the 




difference between bosentan and clobetasol propionate-induced toxicity, we were able to 
conclude that in 2D cultured PHH, BSEP expression does not relate to bile acid concentration. 
As several samples showed no significant differences in total bile acid concentration relative 
to control but still experienced toxic effects, we cannot relate the total bile acid concentration 
to bile acid effects on cell death. It is, therefore, logical to expect that bile acid-mediated 




























5. The effect of different treatments 
on bile acid composition inside the 






5.1 introduction  
This chapter is a continuation of the previous chapter and will look at the bile acid 
metabolomics inside 2D and 3D cultured primary human hepatocytes. in the previous chapter 
we have shown that total bile acid accumulation did not account for toxicity, consequently it 
is important to investigate the individual bile acids and their response to treatments.  
Treatment can cause changes in the bile acid pool, by selectively inhibiting export, changing 
the metabolomics of bile acid formation by interfering with the enzymatic steps or by 
influencing the uptake of bile acids into the hepatocyte. 
5.1.1 primary and secondary Bile acids 
As described in chapter 1.2, de novo synthesis of bile acids in hepatocytes occurs by 
converting cholesterol into bile acids by the action of cytochrome P450 enzymes CYP27A1, 
CYP8B1 and subsequently CYP7A1 [28]. An alternative pathway to produce bile acids occurs 
in peripheral tissues and is initiated by the CYP27A1 and CYP7B1-dependent conversion of 
cholesterol into 27- dihydroxycholesterol, a bile salt precursor that is then taken up by the 
hepatocytes [27]. In both cases only two Bile acids are indicated to be produced by the 
hepatocyte: CA and CDCA. 
After their synthesis, CA and CDCA are either directly transported to the gallbladder and 
subsequently to the intestines or they undergo glyco- or tauro- conjugation making the Bile 
acids CA, with its conjugated forms GCA, TCA and CDCA with GCDCA, TCDCA the only bile 
acids directly produced by the hepatocyte. However, a wider variety of bile acids exist within 
the human genome, explained by the further conversion by the gut-microbiota able to 
produce among others Deoxycholic acid [89]. As these are not primarily produced by the 
hepatocytes they are classified as secondary BAs. The new mixture of primary, conjugated 
primary and secondary Recycling of Bile salts occurs via Apical sodium-dependent bile salt 
transporter (ASBT) in the intestines thereafter bile salts enter the enterohepatic circulation 
and are transported into the hepatocytes by the organic anion transport protein 2 (OATP2) 
and the sodium-taurocholate co-transporting polypeptide (NTCP) [90,91]. Where the cycle 
starts of conjugation, release to the gallbladder and intestines starts anew. This cycle takes 
place around ~20x and permits the liver to only produce ~5% of the primary BA via deNovo 




5.1.2 The toxic and beneficial effect of certain bile acids.  
While previously the total accumulation of bile acids in hepatocytes was considered to be 
toxic, recent investigations show that accumulated bile acids can have different effects within 
the hepatocyte. The first and foremost is that not all bile acids appear to be equally toxic to 
the cell. While no publications can be found that state the IC50 of different bile acids the 
general consensus is that the more hydrophobic a bile acid is, the more toxic it is [93,94]. The 
less hydrophilic bile acids such as UDCA are thought to promote bile acid efflux by stabilising 
the plasma membrane and increasing BSEP localisation in the membrane [95].  
Table 11 hydrophobicity index of Different bile acids obtained from [93,94]. TUDCA = tauro-ursodeoxycholic 
acid, GUDCA = glyco-ursodeoxycholic acid, UDCA = Ursodeoxycholic acid, THDCA = tauro-hyodeoxycholic acid, 
GHDCA = glyco0-hyodeoxycholic acid, TCA = taurocholic acid, GCA = glyco-cholic acid, CA = cholic acid, TCDCA = 
tauro-chenodeoxycholic acid, GCDCA = glyco-chenodeoxycholic acid,  CDCA = chenodeoxycholic acid, TDCA = 
taurodeoxycholic acid, GDCA = glyco-deoxycholic acid, DCA = deoxycholic acid, TLCA = tauro-lithocholic acid, 
























Increased hydrophobic bile acids in the serum, like CDCA and DCA, have been associated with 
colon cancer, gallstones and other gastrointestinal diseases [96]. An example is UDCA, which 
is currently available on the market to treat high cholesterol and gallstones, and to treat 






interacting with several transcription factors, such as FXR, PXR, LXR, the vitamin D receptor 
and the G-coupled bile acid receptor [94,98]. As explained previously FXR plays a crucial role 
in maintaining bile acid homeostasis by influencing the biosynthesis of new bile acids as well 
as bile acid export by being a transcription factor for BSEP-encoding ABCB11. Parks et al. 
found in 1999 that certain bile salts can activate FXR more effectively than others with the 
potency order being: CDCA>DCA>LCA>CA. However, the influence of conjugated forms was 
not investigated [99]. A recent paper found that CDCA can directly bind to FXR and cause 
activation [38]. However, FXR is not specific to the liver and also occurs in other tissues. In the 
intestines, the activation of the FXR receptor has been found to increase the incidence of 
cancer [32]. The wide variety of bile acids and the constant recycling causes major problems 
in identifying bile acids that are important in toxicity and survival.  
This chapter will investigate the effect of different treatments on the concentrations of 
individual bile acids inside 2D and 3D cultured hepatocytes to elucidate the toxicity effect of 






5.2 Results  
Primary human hepatocytes were cultured in 2D and 3D conditions with different drugs as 
described in Section 5.1.4. After their respective incubation times of 6, 24 and 72 hrs, the cells 
and media were separately harvested and analysed by Leiden (see Figure 44). In a targeted 
panel of bile acids, several bile acids were detected to be either inside the cell and/or being 
excreted into the media. By analysing these separately, we were able to investigate the effect 
of drugs on bile acid pool compositions. The results were returned to us as internal standard 
ratios of deuterated bile acid compounds described in chapter (2.3.3). The internal standard 
ratios were also used to create the models in this chapter.  
 
Figure 44. Schematic displaying the way by which samples were generated. This was done for each of the drugs 
investigated. 
 
5.2.1 2D and 3D samples show apparent different metabolomic fingerprint in both media and 
cell lysate.  
Following the removal of outliers, a score scatter plot was created for all samples (Figure 45). 
The data were fitted to a four component PCA-X model (R2= 0.946, Q2=0.859). While some 
outliers can still be observed, no explanation can be found to exclude the samples that are 
still outside the 95% hoteling’s ellipse; they were therefore included in the analysis and 
regarded as a natural variance. Figure 45A shows that a clear distinction between media and 
cell samples can be observed on t[1]. A second separation can be observed between 2D media 




























be made between 2D and 3D cell samples. The associated PCA-X loading plot (Figure 45B) 
shows a separation between the cell and media, and an overall higher association of media 
samples with bile acids. This shows that the bile acid concentration in the media is higher than 






















Figure 45. PCA-X scores and loading scatter plots of all samples (A and B), cell samples compared between 2D and 3D (C and D), and 
media samples compared between 2D and 3D (E and F). Samples were coloured according to primary observations. CL = cell samples, MD 




To further analyse the differences between 2D and 3D samples, the data for the cell samples 
or the media samples were fitted to new models (Figure 45C and D). Individual four 
component PCA-X models for media (R2= 0.934, Q2 = 0.802) and cell (R2=0.946, Q2=0.742) 
samples were created. The individual score plot shows a clear distinction between 2D and 3D 
cell samples on t[1]. The loading plot (Figure 45D), indicates a higher concentration of bile 
acids in 3D cell samples compared to 2D samples. Overall there is a larger variation within the 
individual 3D samples compared to the 2D samples, expressed by the wider spread across the 
t[1]. Within the media samples, a clear separation can be observed between 2D and 3D on 
both the t[1] and t[2]. The associated loading plot (Figure 45F) indicates that 2D media 
samples contain more GCDCA, GCA, GDCA, TCDCA, GUDCA, TLCA-3S, THDCA, and TCA while 
3D samples have a higher concentration of CDCA, DCA, and CA. 
Univariate analysis of 2D and 3D samples  
The univariate analysis of 2D and 3D samples (see Figure 46) reveals that the 2D media 
samples contain significantly higher concentrations of CA, GCA, CDCA, GCDCA, TCDCA, DCA, 
GDCA, TDCA, GUDCA, and THDCA. However, this conclusion cannot be drawn for TCA and 
TLCA-3S due to missing samples. This is different from the 3D samples where only CA, GCA, 
CDCA, GCDCA and DCA have significantly higher concentrations in the media than in cells. The 
difference between 2D and 3D samples could be due to the near normal expression of 
proteins in the 3D cultures. The uptake of bile acids and therefore the recycling could be 
simply be better. Another explanation could be that due to the increased Cyp450 enzyme 
expression levels in 3D cultures, cells are metabolizing the compound, causing different 
responses between 2D and 3D samples.  
3D cells contain significantly higher concentrations of CA, but none of the other bile acids are 
significantly higher than in 2D cells. In 3D media, CA, CDCA and DCA are significantly higher 
than in 2D media. However, in 2D media GCA, TCA, GDCA, TCDCA, GDCA, TDCA, GUDCA, and 
THDCA are significantly higher in concentration. This is interesting as CA, CDCA are primary 
bile acids while the others are secondary bile acids. As the formation of secondary bile acids 
is generally thought to involve bile acid conversions by the gut micro-organisms, and this 
study was performed under sterile conditions, the results could point to the production of 
secondary bile acids by 3D cells. Moreover, 3D cells are able to produce primary bile acids 

























































































































































































































































































































































































































































































Figure 46. Box and whisker plot (min to max) of univariate analyses of 2D cell and media samples as well as 3D 






5.2.2 The effect of treatment and time on bile acid compositions within 2D cells and media 
To evaluate the effect of treatment and time on samples, individual PCA-X models were 
created (see Table 3 for R2 and Q2 values). Figure 47 displays the individual score plots of the 
2D samples for either cell or media samples with their respective loading plots. 
2D cells 
In Figure 47A the individually calculate scores for the 2D cell samples are displayed. To 
indicate the location of the control samples (DMSO treated), a grey ellipse was drawn around 
them. While no clusters other than the grey-circled cluster can be observed, several samples 
are located outside the cluster. These samples consist of cells treated for 6 hrs with estradiol, 
which show a higher concentration for GCDCA. For a single sample treated with estradiol for 
24 hrs, the loading plot indicates higher concentrations of CDCA, GDCA, TCDCA and CA. For a 
single sample treated for 72 hrs with bosentan, the loading plot indicates higher 
concentrations of TCDCA, GCDCA and CDCA. Finally, the cells treated with cycloheximide for 
72 hrs are associated with higher concentrations of GUDCA, THDCA.  
The univariate analysis of the 2D cell samples (see Figure 48) shows that different treatments 
have different effects on bile acid pools within the cells of 2D cultured PHH. Cyclo-hexamide 
only showed a significant decrease in GCDCA at 72 hrs. This could be due to the death of cells 
and the subsequent release of the bile acids into the media causing the actual cell 
concentration to drop. Estradiol showed a significant decrease at 6 hrs for TDCA compared to 
DMSO control. At 24 hrs estradiol showed no significant differences to DMSO control, 
nonetheless at 72 hrs a significant decrease in GCA and GCDCA can be observed. However, 
after 72 hrs of treatment these cells had lost viability (see chapter 4, Figure 35). Bosentan is 
a strong direct inhibitor of BSEP and it would be expected that the concentrations of all bile 
acids in the cytoplasm will be increased. But this is not was can be observed in the data. 
Bosentan only significantly increased TDCA after 6 hrs of treatment. After 24 hrs no significant 
changes were detected, whereas at 72 hrs a significant decrease in GCA and GCDCA was 
observed. Clobetasol Propionate is a BSEP inhibitor, but one that does not cause liver injury. 
A significant increase was obtained at 6 hrs for TCDCA and TDCA. At 24 hrs TDCA was 




Clobetasol propionate was also compared to bosentan to test if any differences in bile acid 
specificity can be found, possibly explaining why bosentan is toxic while clobetasol propionate 
is not. What could be observed is a significant difference at 6 hrs for TCDCA between bosentan 
and clobetasol propionate. However, this observation was not repeated in any other time 





















Figure 47. PCA-X scores and loading plots for 2D cell samples (A and B), and media samples (C and D). Treatments are displayed as two 
letter indicating abbreviations followed by the hours of incubation.: BS= bosentan, CH = cyclo-hexamide, CP = clobetasol propionate, DM 
= DMSO, ES = estradiol. Times: 06 = 6hrs, 24 = 24hrs, 72 = 72hrs. Grey circle indicates the location of the DMSO samples, yellow circle = 
location of 6 hrs data, while the purple circle indicates the location of 24 hrs and 72 hrs. red circle identify the primary bile acids, and blue 






In the media samples, a more apparent separation between the samples was observed, with 
the grey circle indicating the location of DMSO vehicle control samples (Figure 47C). 
Treatment samples show, in general, a higher expression of all the bile acids detected in the 
panel, compared to DMSO. While a distinct separation was not observed, a shift on the t[2] 
was obtained as time is increased (yellow circle = 6 hrs, purple circle = 24 and 72 hrs). The 
associated loading plot (Figure 47C) indicates that the concentrations of THDCA, TDCA, GDCA, 
TCDCA, GUDCA, TCA, GCDCA, GCA increase over time.  
Interestingly this shows that 6 hrs samples have a higher concentration of CDCA, DCA, and CA 
while 24 hrs and 72 hrs contain more tauro- and glyco-conjugated forms: THDCA, TDCA, 
GDCA, TCDCA, GUDCA, TCA, GCDCA, GCA.  
The univariate analysis of the 2D media samples indicate that the bile acid pool in the media 
is also affected by the drug.  
Cycloheximide showed no significant differences in bile acid concentration after 6 or 24 hrs 
of treatment, while at 72 hrs a significant increase in TDCA, THDCA and TLCA-3S was observed 
compared to DMSO control. Estradiol showed significant increases at 6 hrs for CDCA. At 24 
hrs CDCA and TDCA were both significantly increased, whereas at 72 hrs these changes were 
no longer observed. Bosentan caused a significant increase in CDCA at 6 hrs and 24 hrs, 
whereas clobetasol propionate was not significantly different from DMSO control at any time 
point for any bile acid. No significant changes were detected between clobetasol propionate 






































































































































































































































































































































































Figure 48. Univariate analyses of bile acids in 2D cell samples displayed as box and whisker plot (min+ max) * 
indicates comparison to DMSO control or otherwise indicated with a line, # indicates a significant difference 
from the samples previous time point. (N=4) * and # indicate significant differences as stated in chapter 2.4 by 
two-way ANOVA. (DMSO = grey, cycloheximide = blue, estradiol = red, bosentan = orange, clobestasol 










































































































































































































































































































































































































































Figure 49 Univariate analyses of bile acids in 2D media samples. displayed as box and whisker plot (min+ max) * 
indicates comparison to DMSO control or otherwise indicated with a line, # indicates a significant difference 
from the samples previous time point. (N=4) * and # indicate significant differences as stated in chapter 2.4 by 
two-way ANOVA. (DMSO = grey, cycloheximide = blue, estradiol = red, bosentan = orange, clobestasol 





5.2.3 The effect of treatment and time on bile acid within 3D cell and media  
To evaluate the effect of treatment and time on 3D cell and media samples, individual PCA-X 
models were created (see Table 11 for R2 and Q2 values). Figure 50 displays the individual 
score plots of the 3D samples for either cell or media samples with their respective loadings. 
3D cell  
The effect of treatment and time on 3D samples was more defined than the effect on 2D 
samples. The PCA-X model for 3D cell values indicates a time-dependent shift of samples over 
the t[1]; 6 hrs samples are indicated by a yellow ellipse while later samples are indicated with 
a purple circle. The purple circle indicates that 24 and 72 hrs samples have a higher 
concentration of all the detected bile acids. In the associated loading plot (Figure 50B), Figure 
50B, a clear grouping or GCDCA and GCA can be seen, indicating a strong positive correlation 
between the two. These two variables are associated with the samples in the upper right 
corner of the score plot. In particular: 24 and 72 hrs for bosentan, and 72 hrs for DMSO 
suggesting that these samples have higher concentrations of GCDCA and GCA. The grey circle 
indicates the location of the control samples (DMSO), with a very tight clustering of the 6 and 
24 hrs samples and a shift to the right over the t[1] for 72 hrs samples. These data suggest 
that at 72hrs the cells contain higher concentrations of GCDCA and GCA.  
The univariate analyses for 3D cell samples (see Figure 51) treated with cyclo-hexamide 
showed no significant changes for the first 6 hrs. However, after 24 hrs a significant increase 
was observed for CDCA and DCA. After 72 hrs a significant increase was observed for CA, 
CDCA, TCDCA, DCA and TDCA, whereas a significant decrease was seen for GCA. An increase 
in bile acids at 72 hrs for the cell samples might be interesting as the cells were no longer 
viable at 72 hrs. Possibly, a few surviving cells must have had very high concentrations of the 
bile acids. Estrogen significantly increased concentrations of CDCA and DCA after 6 hrs of 
treatment in 3D cultured cells. After 24 hrs of incubation with estrogen, CA, CDCA and DCA 
were significantly increased but at 72 hrs only DCA and TCDCA were significantly increased. 
Bosentan caused CDCA and DCA to accumulate within the cell compared to DMSO at 6hrs. 
After 24 hrs the effect was lost for CDCA but DCA remained significantly elevated compared 
to DMSO. At 72 hrs, however, bile acid concentrations were not significantly different from 
the DMSO control. Clobetasol propionate caused DCA to accumulate within the 3D cultured 




but TCDCA had accumulated in the cell. Most notable is the comparison between bosentan 
and clobetasol propionate after 72 hrs. The GCDCA concentration was significantly higher in 
cells treated with bosentan but TCDCA was significantly higher in cells treated with clobetasol 
propionate. It is interesting to note that both GCDCA and TCDCA are conjugated forms of 
CDCA that are known to activate FXR and enhance BSEP expression.  
3D media 
In 3D media samples (see Figure 50C), a time-dependent shift can be observed over the t[1], 
the associated loading plot suggest a general increase of bile acid concentrations. 
Interestingly the two bosentan samples for 72hrs are the furthest outliers and associate most 
with GCDCA and GCA.  
In the univariate analysis of the 3D media samples (see Figure 52a) cycloheximide only caused 
an accumulation of DCA at 24 hrs after which levels fell back to normal levels compared to 
the DMSO control. Estrogen significantly decreased GCA and a significantly increased TCDCA 
in the media collected after 72 hrs of treatment. Bosentan significantly increased DCA at 6 hrs 
and 24 hrs and CDCA at 72 hrs when compared with the DMSO control. The exposure to 
clobetasol propionate significantly decreased the accumulation of GCA, and increased the 
accumulation of TCDCA at 72 hrs. The comparison of the data for bosentan and clobetasol 
propionate showed that GCDA was significantly increased in bosentan treated samples 
whereas TCDCA was significantly increased in the clobetasol propionate treated samples. This 
is the same change as seen for the cell samples, pointing to increased production and the 

























Figure 50 PCA-X score and loading plots for 3D cell samples (A and B), and media samples (C and D). Treatments are displayed by two 
letter abbreviations followed by the hours of incubation.: BS= bosentan, CH = cyclo-hexamide, CP = clobestasol propionate, DM = DMSO, 
ES = estradiol. Times: 06 = 6hrs, 24 = 24hrs, 72 = 72hrs. Grey circle indicates the location of the DMSO samples, yellow circle = location of 
6 hrs data, while the purple circle indicates the location of 24 hrs and 72 hrs. red circle identify the primary bas, and blue the conjugated 















































































































































































































































































































































































Figure 51 Univariate analyses of bile acids in 3D cell samples displayed as box and whisker plot (min+ max) * 
indicates comparison to DMSO control or otherwise indicated with a line, # indicates a significant difference 
from the samples previous time point. (N=4) * and # indicate significant differences as stated in chapter 2.4 by 
two-way ANOVA. (DMSO = grey, cycloheximide = blue, estradiol = red, bosentan = orange, clobestasol 


































































































































































































































































































































































































Figure 52 Univariate analyses of bile acids in 3D media samples displayed as box and whisker plot (min+ max). * 
indicates comparison to DMSO control or otherwise indicated with a line, # indicates a significant difference 
from the samples previous time point. (N=4) * and # indicate significant differences as stated in chapter 2.4 by 
two-way ANOVA. (DMSO = grey, cycloheximide = blue, estradiol = red, bosentan = orange, clobestasol 







5.2.4 Clustering of bile acids in 2D and 3D cultured samples  
The loading plot of the 2D media samples in Figure 47D shows two distinct clusters of 
variables; this clustering is not, however, observed for the 2D cell samples. It is interesting to 
note a separation between unconjugated (red circle) and conjugated (blue circle) bile acids 
was observed in 2D media. As this separation was seen in the same direction as the time-
dependent shift, it is very likely that the concentration of unconjugated bile acids lowers over 
time due to these bile acids being conjugated within the cell, thus increasing the 
concentration of secondary bile acids. In the 2D cell samples, no separate clusters of bile acids 
were observed, which can indicate that conjugated forms of bile acids are preferentially 
transported to the media, or that 2D cells produce CDCA, DCA, and CA. Therefore, even 
though the conjugated bile acid concentration increases, the concentration of CDCA, DCA and 
CA is not decreasing over time.  
In the 3D samples, two distinct clusters can be observed within the loading plots of either cell 
and media. Within the cell samples, the first cluster consists of GCDCA and GCA (blue circle) 
while the second cluster consists of DCA, CDCA, TCDCA, GUDCA and CA (red circle). While a 
general shift across the t[1] to higher bile acids concentrations can be observed over time, 
the red cluster is more associated with 24 and 72hrs cycloheximide, 24 and 72 hrs estradiol, 
24 and 72 hrs bosentan and 72 hrs clobetasol propionate. The blue cluster is associated with 
higher concentrations in the 24 and 72 hrs Bosentan as well as a solitary 72 hrs DMSO 
samples, rather than with a time-dependent element.  
In the media samples, a clear distinction between two clusters of variables can be observed, 
with the first group consisting of GCDCA and GCA (indicated by the blue circle) and the second 
consisting of TCDCA, CA, DCA, GUDCA) (indicated by the red circle). However as there is no 
clear separation in the 3D score plot, drawing a conclusion to the meaning of the variable 






5.2.5 Early indications of toxicity  
To identify early indications of toxicity during different treatments, new PCS-X models were 
created for cell and media samples from the 2D and 3D cell cultures (see Table 12 for several 
components, R2 and Q2 values). In this thesis only the 6hrs data is displayed as cells were 
assumed to be 100% alive at that time; the viability of each sample was measured at 72hrs.  
In the 2D cell samples (Figure 53A) a shift in the estradiol samples towards TDCA, GUDCA, 
GCDCA and GCA was observed (Figure 53B). None of the other samples shows any change at 
6hrs even though bosentan and clobetasol propionate had a significant effect on cell survival 
compared to DMSO samples at 72 hrs. Normalised ATP expression was only at 26% and 56% 
respectively for bosentan and clobetasol propionate when compared to DMSO samples, while 
cycloheximide showed no survival at 72hrs (0%). In the media data (Figure 53C), there is a 
diagonal shift over t[1] and t[2] with DMSO samples mostly having higher concentrations of 
CA and GDCA (Figure 53D). Clobetasol propionate, however, had higher concentrations TCA, 
TLCA-3S, TDCA, GUDCA, THDCA, and TCDCA.  
In 3D samples, only cycloheximide treated samples showed signs of toxicity, showing 0% 
normalised ATP concentration at 72hrs when compared to DMSO. A clear separation between 
healthy samples and cyclo-hexamide treated samples can be observed on 6hrs 3D cell 
samples (Figure 53E). The corresponding loading plot indicates that healthy samples have 
higher expression of all bile acids. 3D media samples did not show any kind of clustering 

































Figure 53. PCA-X score and loading plots for the 6hrs data for 2D cell (A and B) and media (C and D) and 3D cell (E and F), and media 
samples (G and H). Treatments are displayed as two letters abbreviations followed by hours of incubation: BS= bosentan, CH = cyclo-
hexamide, CP = clobetasol propionate, DM = DMSO, ES = estradiol. Grey circle indicates the location of the DMSO samples. Colours 
indicate viability of the cell samples at 72 hrs (green = >80%, red = 20-50%, black = 0-20%). Red circle identifies the primary bile acids, 








Table 12 showing the predicted values of components R2 and Q2 in the multivariate analysis.  
 Number of 
components 
R2 Q2 
All data 4 0.946 0.859 
2D vs 3D cell 4 0.946 0.742 
2D vs 3D media 4 0.934 0.802 
2D cell 4 0.975 0.851 
2D media 4 0.949 0.822 
3D cell 4 0.969 0.838 
3D media 3 0.932 0.765 
2D cell 6hrs 2 0.935 0.772 
2D media 6hrs 6 0.987 0.801 
3D cell 6hrs 4 0.980 0.851 







5.3 Discussion of the results. 
Overall very few papers have been published on the metabolism of bile acids in human cell 
lines, whereas there is a lot of information regarding bile acid pool changes in mice and rats. 
However, regarding bile salt metabolism, these mammals have three primary bile acids (CA, 
CDCA, UDCA, and the mouse rodent specific αMCA and βMCA) compared to two in humans 
(CA and CDCA), and they are therefore very different from humans [100]. They also have 
several bile salts that are absent in the human (αMCA and βMCA and their conjugated forms) 
and compared to humans a much larger portion of bile acids originate from the acidic 
pathway (5% compared to 25%). Furthermore, rats do not have a gallbladder while humans 
and mice do [101]. Finally rodents have a much lower hydrophobicity index indicating that 
bile acids are less toxic to them [93]. We therefore need to be especially careful when 
extrapolating data regarding bile acid formation and the influence of drugs from rodents to 
human.  
My study shows that PHH are a good alternative to rodent studies in order to investigate the 
changes that occur in bile acid pool and accumulation, they were easy to treat and investigate. 
There are, however, a few downsides to PHH: due to the lack of gut microbiota there are very 
few secondary bile acids present in the samples. The secondary bile acids that were found in 
this study where completely unexpected and are currently under investigation.  
The definition of the primary bile acids was first published in 1961 by Bergstrom et al. 
Bergstrom won the Nobel prize in physiology or medicine in 1982 for his discoveries on 
prostaglandins. While his experimental set-up is no doubt correct [original experimental 
paper is not accessible], time has moved on and with the newer equipment we are now able 
to pick up minute differences. Sama I. Sayin et al. [102] looked at germ free and conventual 
raised mice, and were able to detect several more bile acid at this point in time. This supports 
the idea that techniques have become more sensitive. However it is specifically stated that 
TUDCA is considered a secondary bile acid in humans while in mice TUDCA is recognized as a 
primary bile acid [26].  
My in-depth literature research suggests that no experiments with modern technology has 




Sharanek et al. 2015 [103] found that FCS and BCS in cell media contains bile acids. However, 
bile acids in the FCS used in our experiment was tested to be below detection levels. 
While we are still investigating the origin of secondary bile acids in this study the presence of 
DCA in the samples can be explained in several ways: 
1.  DCA is a primary bile acid and the cells are therefore able to produce DCA. In addition, 
they are able to produce CA and CDCA. An argument for this is that in 3D cells, where 
P450 enzymes are considered to be expressed normally, DCA is always clustered 
together with CA and CDCA. 
2. DCA is an artefact and the cells are able to produce this bile acid due to a chemical in 
the media culture. Within humans this reaction would not be feasible or occurs in very 
small amounts 
3. DCA was present in the media and accumulated in the cells to such an extent that 
detection was possible. However, none could be found in the media itself.  
At this point we cannot conclusively say where DCA originates from, but its presence was an 
unexpected blessing. DCA is one of the most toxic bile acid in the human body (according to 
the hydrophobicity index), accordingly it is vital to investigate the effect test compounds have 
on DCA concentration inside the cell in regards to toxicity studies [104].  
Luo et al 2018. [104] assesses the use of bile acids as biomarkers for liver disease. These 
authors found that in healthy patients, DCA accounted for 12% of the total bile acids serum 
pool, but in patients with liver disease DCA only accounted for 0.3%. They further observed 
that the entire bile acid pool shifted within patients with hepatic injury, leading to an increase 
in TCA, TCDCA, GCA, and a decrease in GDCA, DCA, TDCA, CA, and CDCA compared to healthy 
individuals. These findings indicate that when looking at bile acid-induced injury we need to 
look at the bile acid pool composition rather than just one bile acid or total amount of bile 
acid.  
DCA is also able to influence intracellular signalling through membrane perturbations [105]. 
DCA causes an increase of cholesterol at the plasma membrane which in turn increases BSEPs 
ability to transport bile acids [106]. Additionally, Jean-Louis et al 2006 found that depending 




such as causing membrane capping, disrupting membrane structure (specifically DCA), 
modulating sphingomyelin and ceramide levels (see chapter 6 for further information), 
internalization of caveolin-1, activation of tyrosine kinases [105]. The changes in DCA were 
comparable with changes that occur by apoptosis-inducing agents, they further found that 
reducing the cholesterol accumulation in the membrane caused by DCA reverted the changes 
at the membrane back to normal [105]. DCA is further able to activate the EGFR – MAPK - 
ERK1/2 pathway via non-canonical activation in colon cancer cells after it was shown that DCA 
is able to activate the same pathway in rat hepatocytes [107]. Overactivation of this pathway 
leads to uncontrolled proliferation and cell survival in colon cancer cells. This is important 
because in this chapter we have shown in the univariate analysis of 3D cells that DCA was 
significantly upregulated in cells treated with estradiol, bosentan and clobetasol propionate 
at 6 hrs, and cycloheximide, estradiol bosentan, and clobetasol propionate at 24 hrs. 
However, at 72 hrs DCA was only upregulated in cyclohexamide treated 3D cells. This was the 
only sample that showed significant toxicity in the 3D samples.  
The gut-microbiome and liver axis for bile acids is very important, the gut microbiome has 
been found to influence liver cancer via natural killer T cells [108]. Primary bile acids increased 
CXCL16 expression responsible for NKT cell accumulation, whereas secondary bile acids 
reduced CXCL16 expression. A treatment with vancomycin to remove bacteria responsible for 
secondary bile acids transformations was enough to increase NKT cell accumulation and 
decrease liver tumours [108]. 
Bile fingerprinting via UPLS-MS has shown that TCA secretion was significantly increased in 
bile samples obtained after liver transplants and that this might be linked to regeneration 
[109]. TCA was significantly higher in 2D media treated with clobetasol propionate, but not in 
any of the other samples. This might explain why clobetasol was less toxic in our experiment 
as well as why it does not cause toxicity in humans.  
However, future work should include different cell donors and more samples. In this way, the 
clustering in the multi variate analysis will be more complete and indicative for toxicity. 
However, this chapter demonstrates the achievability of MS/MS analyses to explain iDILI and 












6. Signalling and peroxidised lipid 
profiling in 2D and 3D cultured primary 






6.1 The different lipids and the metabolic pathways in this study.  
Our understanding of the membrane has evolved from a simple lipid bilayer with embedded 
proteins to a complex dynamic and heterogenous patchwork of microdomains that contain 
ion channels, transporters and other proteins, and cholesterol- and sphingolipid-rich lipid 
rafts. In multicellular organisms, lipids have been recognised as signalling molecules since the 
early 1930s, when ”slow-reacting substance of anaphylaxis” (SRS-A) was identified. Around 
the same time, the vasodilating effect of prostaglandins was described [110]. Since then, 
more and more lipids were identified that are involved in signalling and deemed responsible 
for the communication between the cells either by cell-cell contact or through soluble factors. 
The regulation of these lipids is critical and tightly regulated. While lipids are typically thought 
to be building blocks of membranes and stores of metabolic energy [111], the lipids in this 
chapter will be described as signalling mediators in cellular responses to drugs.  
The metabolic system of a multicellular organism is very complex as the maintenance of 
homeostasis is crucial. A vast range of metabolic pathways is responsible for carbohydrate 
and energy metabolism, and the biosynthesis of lipids, lipoproteins, amino acid, nucleic acid 
and proteins [112]. The Kyoto Encyclopedia of Genes and Genomes (KEGG) provides a large 
database on investigations of metabolic pathways 
(https://www.genome.jp/kegg/pathway.html)[113–115] . The next paragraphs describe the 





















Figure 54. KEGG pathway of linoleic acid metabolism. Displayed in red are metabolites detected and described in this chapter. White rectangles 
depict genes products, mostly proteins but also RNA. Rounded rectangles depict another map. Circles depict chemical compound, DNA and other 




6.1.1 Metabolites in linoleic acid metabolism  
Linoleic acid is an essential omega-6 fatty acid that is obtained from our diet and is vital for 
maintenance of cell integrity [116]. It is situated in the middle of the metabolic KEGG pathway 
in Figure 54 (red dot). There are three main pathways by which linoleic acid can be 
metabolised. In the first pathway, linoleic acid is metabolised to arachidonic acid (AA) via y-
linolenate by a desaturase enzyme (top left of Figure 54). This pathway will mostly promote 
an inflammatory response downstream from AA. The second pathway uses Cyp450 enzymes 
to transform linoleic acid into 12,13-DHOME; 9,10-DHOME and THF-diols (bottom left of 
Figure 54). In the third pathway, auto-oxidation converts linoleic acid into 9-sOxoODE; 
9,12,13-TriHOME; 9,10,13-TriHOME; 9,12,13-TriHOME and 13-OxoODE. All the products from 
linoleic acid are known to have effects on living organisms or tissues) and are essential in 
physiological and pathological circumstances. The metabolites indicated in red in Figure 54 
were detected in this chapter. They have the following bioactivities:  
-  (+/-)-20-hydroxy-4Z,7Z,10Z,13Z,16Z,18E-docosahexaenoic acid ((+/-) 20-HDoHE) is an 
auto-oxidation product of docosahexaenoic acid (DHA) in vitro and is a potential 
marker for oxidative stress in the brain and retina where DHA is an abundant 
polyunsaturated fatty acid [117].   
- (±)12,13-dihydroxy-9Z-octadecenoic acid (12,13-DiHOME) is the diol form of 
(±)12(13)-EpOME (isoleukotoxin) and is formed by P450 enzymes from linoleic acid. It 
is known to increase after spinal cord injury and burn injuries in rats. It was found to 
increase fatty acid uptake in brown adipose tissue and was elevated in concentration 
in mice with hepatocellular carcinoma [118,119]. 
- (±)-9-hydroxy-10E,12Z-octadecadienoic acid (9-HODE) is one of two racemic 
monohydroxy fatty acids resulting from the non-enzymatic oxidation of linoleic acid. 
Oxidised LDL contains significant amounts of esterified 9-HODE [120].  
- (±)9,10-dihydroxy-12Z-octadecenoic acid (9,10-DiHOME) is a degradation product of 
leukotoxin, the toxicity of which is associated with mitochondrial dysfunction and 
apoptosis. In renal proximal tubular cells, 9, 10-DiHOME has been directly implicated 
as cytotoxic agent responsible for cell death [121–123].  
- 9S,10S,13S-trihydroxy-11E-octadecenoic acid (9,10,13-TriHOME) is an oxylipin derived 




6.1.2 Metabolites in arachidonic acid metabolism 
AA is an omega-6-fatty acid that is obtained via another metabolic pathway from linoleic acid, 
as described in Chapter 6.1.1. AA is present in the membranes of most cells and is most 
abundant in the brain, muscles and liver, where it plays an important role as a lipid secondary 
messenger. It is often considered to be a key player in mediating inflammatory signals. Its 
metabolism is displayed in Figure 55. In the test panel used for these experiments, we were 
only able to find three of the metabolites in the arachidonic pathway. However, the evidence 
for AA involvement in a pro-inflammatory pathway is ambiguous as higher levels of AA may 
reduce systemic inflammation by reducing pro-inflammatory IL-6 and IL-1 levels and 
increasing anti-inflammatory tumour necrosis factor-beta (TNFb). In this panel, we were able 





Figure 55. KEGG pathway of arachidonic acid metabolism. Displayed in red are metabolites detected and described in this chapter. White rectangles 
depict genes products, mostly proteins but also RNA. Rounded rectangle depicts another map. Circles depict chemical compound, DNA and other 




- prostaglandin f2a (PGF2a) is naturally occurring prostaglandin, and through the 
activation of the Akt/mTOR pathway responsible for muscle growth [123,124].  
- 11-deoxy-13,14-dihydro-15-keto-11β,16.xi.-cycloprostaglandin E2 (bicyclo-PGE2) is a 
stable breakdown product of prostaglandin E2 (PGE2) and 13,14-dihydro-15-keto 
PGE2 and is measured instead as a marker for the biosynthesis or metabolism of PGE2. 
PGE2 is the most biologically active of the mammalian prostaglandins and is known to 
increase the production of cAMP and enhance the effect of bradykinin and histamine 
[125].  
- linoleoyl ethanolamide (LEA) is the ethanolamide form of linoleic acid, which can 

















6.1.3 N-acylethanolamines (NEAs) (Figure 56) 
NAEs are released by N-acylphosphatidylethanolamine (NAPE) in response to a variety of 
stimuli, and release and accumulation has been attributed to biological activities such as 
neurotransmission, membrane protection and immunomodulation. The following NEAs were 
detected in this panel:  
- oleoyl ethanolamide (OEA) is a naturally occurring lipid present in both plant and 
animal membranes and is part of the N-acylethanolamines (NAEs). OEA is known to 
inhibit sphingolipid signalling pathways by blocking the effect of TNF on intracellular 
Ca2+ concentrations. In adipocytes and hepatocytes, OEA inhibits mitogenic and 
metabolic signalling by the insulin receptor and produces glucose intolerance. It is also 
known to reduce visceral and inflammatory responses through a PPAR-alfa activation-
independent mechanism [126].  
- palmitoyl ethanolamide (PEA) is present in most tissues of mammals. While initially 
described as a type 2 cannabinoid receptor agonist, this has now been overturned as 
it was shown that PEA is unable to bind to any cannabinoid receptors. It is currently 
unknown which physiological stimuli regulate PEA levels. However, many studies 
show an increase of PEA during cellular stress, particularly tissue injury. While PEA 
does not have anti-inflammatory abilities, it appears to interact with the LPS-
stimulated pathway. Besides its anti-inflammatory effects, it also has analgesic, 
neuroprotective, and anti-epileptic properties [126]. 
- stearoyl ethanolamide (SEA) inhibits lipid peroxidation in the membranes of 
mitochondria in the liver during acute hypoxia and has been found to have a pro-





















Figure 56. KEGG pathway of PPAR signalling. Displayed in red are metabolites detected and described in this chapter. White rectangles depict genes 
products, mostly proteins but also RNA. Rounded rectangles depict another map. Circles depict chemical compounds, DNA and other molecules. 




6.1.4 Metabolites in sphingolipid metabolism (Figure 57) 
Sphingomyelin (SM) and its metabolic products are now known to have secondary messenger 
functions in a variety of cellular signalling pathways. Notably, the sphingolipid metabolites 
ceramide (Cer) and sphingosine-1-phosphate (S1P) have emerged as a new class of potent 
bioactive molecules. Ceramide can be generated de novo or by hydrolysis of membrane 
sphingomyelin by sphingomyelinase (SMase). Ceramide is subsequently metabolised by 
ceramidase to generate sphingosine (Sph), which in turn produces S1P through 
phosphorylation by sphingosine kinases 1 and 2 (SphK1, 2).  
- sphinganine (SPHA C18_0) blocks post-lysosomal cholesterol transport by inhibiting 
LDL-induced esterification of cholesterol and causes unesterified cholesterol to 
accumulate in the perinucleus vesicles. Is has been suggested that endogenous SPHA 
inhibits cholesterol transport in Niemann-Pick Type C disease [124,127].  
- sphingosine (SPH C18_1) is a derivative of sphinganine and is a major class of 
sphingolipids in mammals. It can be phosphorylated in vivo via two kinases 
(sphingosine kinase type 1 and type 2) leading the formation of the potent signalling 












Figure 57. KEGG pathway of sphingolipid metabolism. Displayed in red are metabolites detected and described in this chapter. White rectangles 
depict genes products, mostly proteins but also RNA. Rounded rectangles depict another map. Circle depicts chemical compounds, DNA and other 




6.2 Results  
6.2.1 2D and 3D samples show apparent different metabolic fingerprint for signalling lipids in 
both media and cells. 
A three-component PCA-X model was fitted over the samples (R2= 0.921 and Q2=0.798) and 
produced a score plot shown in Figure 58A. Three distinct groups can be identified, 2D cell, 
3D cell and the third group consisting of a mixture of both the 2D and the 3D media samples. 
Consistent with the loading plot, 2D and 3D media contain more of each of the signalling lipids 
and 3D cell lysates. To investigate the difference within 2D and 3D samples in more detail, 
two-component PCA-X models were fitted over either the cell samples (Figure 58C, R2=0.939 
and Q2=0.9) or the media samples (Figure 58E, Q2=0.63 and Q2=0.189).  
Figure 58C shows distinct clustering of 2D samples vs 3D samples. The 3D samples correlate 
to an increased concentration of all lipid variables. A clustering of SPHA and SPH can be seen 
in the loading plot compared to the other lipids in the lower right quadrant. The media 
samples show a less distinct pattern of separation, but a shift over the t[2] can be observed. 
The 3D samples show a stronger association with PEA, OEA, PGE and SEA expression than 2D 
samples, indicating that higher concentrations of PEA, OEA and SEA were detected in the 3D 
samples than in the 2D samples.  
To confirm whether these changes are significant, a univariate analysis was performed for 
each individual signalling lipid (see Figure 60). Compared to 2D cell samples, 3D cells express 
significantly more 12,13-DiHOME (p= <0.0001), 9-HODE (p= <0.0001), 9,10-DIHOME (p= 
<0.0001), 9,10,13-TriHOME (p= <0.0001), LEA (p= <0.0001), OEA (p= <0.0001), PEA (p= 
<0.0001), PGF2a (p= <0.0001), SEA (p= <0.0001), SPHA (p= <0.0001), SPH (p= <0.0001) and 
Bicyclo-PGE2 (p= <0.0001). 
Compared to 2D media samples, the 3D media samples also express significantly more 12,13-
DiHOME (p= 0.0283), 9-HODE (p= <0.0017), (+/-) 20-HDoHE (p= <0.0001), LEA (p= <0.0001), 
OEA (p= <0.0001), PEA (p= <0.0001), PGF2a (p= <0.0065), SEA (p= <0.0002), and Bicyclo-PGE2 




























Figure 58. PCA-X scores and loading scatter plots of all samples (A and B), cell samples compared between 2D and 3D (C and D), and 
media samples compared between 2D and 3D (E and F). Samples were coloured according to primary observations. CL = cell samples, MD 































Figure 59. PCA-X scores and loading scatter plots of 2D samples (A), cell and media samples compared for 2D (A) and 3D cell and media 
samples observed (C) together with their loading plots. Samples were coloured according to primary observations. CL = cell samples, MD 





6.2.2 Separation between media and cell samples in both 2D and 3D. 
To test whether there was a difference between excreted lipids and those retained within the 
cells, the samples were divided into 2D and 3D, and a one and two-component PCA-X was 
fitted over the data. The samples were then coloured according to their primary observation 
ID into cell and media. In the 2D model in Figure 59A, (R2= 0.82, Q2=0.71), a clear separation 
of t[1] can be seen between media and cell samples. Though only one component is present 
in the model, Figure 59B shows that media samples contain more lipids than the cell lysate. 
These results indicate that most lipids are exported out of the cell or released from the cell 
membrane.  
The PCA-X model fitted over the 3D samples (R2=0.781 and Q2=0.579) is shown in Figure 59C. 
The model shows once again a clear separation between media and cells. This separation is 
explained by t[1]. Figure 59D indicates that in the 3D samples the lipids remain within the cell 
or bound to the membrane. Interestingly this observation is the opposite to that for 2D 
samples.  
The univariate analysis of the individual signalling lipids showed significant differences, where 
2D media samples express significantly more 12,13-DiHOME (p= <0.0001), 9-HODE (p= 
<0.0001), 9,10-DIHOME (p= <0.0001), 9,10,13-TriHOME (p= 0.0002), LEA (p= <0.0001), OEA 
(p= <0.0001), PEA (p= <0.0001), PGF2a (p= <0.0001), SEA (p= 0.0002), and Bicyclo-PGE2 (p= 
<0.0001) than 2D cell samples.  
Interestingly, within 3D samples, the media contain significantly less 12,13-DiHOME (p= 
0.0283), 9-HODE (p= 0.0017),(+/-) 20-HDoHE (p= <0.0001), LEA (p= <0.0001), OEA (p= 
<0.0001), PEA (p= <0.0001), PGF2a (p= 0.0065), SEA (p= 0.0002), and Bicyclo-PGE2 (p= 










































































































































































































































































































































































Figure 60 Univariate analyses of signalling lipids in 2D cell and media samples as well as 3D cell and media 
samples displayed as box and whisker plot (min+ max). (N=50) * indicate significant differences as stated in 
chapter 2.4 by two-way ANOVA. (DMSO = grey, cycloheximide = blue, estradiol = red, bosentan = orange, 










6.2.3 The effect of treatments and time on signalling lipid fingerprints.  
To investigate the effect of treatments on signalling lipid metabolism, PCA-X models were 
fitted over 2D cell data, 2D media samples as well as the 3D cell samples and 3D media 
samples. However, none but the 3D media sample models had a positive R2 and Q2 value for 










The univariate analysis of 2D cell, 2D media and the 3D cell samples are displayed in Figure 
62, Figure 63 and Figure 64, respectively. A two-way ANOVA test was performed to identify 
any significant changes, but none were recognised. A possible explanation of why no model 
could be fitted over the data is that no variance is detected between the samples. The 3D 
media samples, however, showed a far larger variance and a model could, therefore, be fitted 
over the data. The univariate analysis of the 3D media samples showed significant changes at 





Figure 61. PCA-X scores and loading scatter plots of 3D media samples (A and B). Samples were coloured according to primary 
observations. BS= bosentan, CH = cyclo-hexamide, CP = clobetasol propionate, DM = DMSO, ES = estradiol. Times: 06 = 6hrs, 24 = 24hrs, 
72 = 72hrs. Grey circle indicates the location of the DMSO samples, yellow circle = location of 6 hrs data, while the purple circle indicates 



















































































































































































































































































Figure 62. Univariate analysis of signalling lipids in 2D cell samples. Colours indicate same treatment as indicated 
in Chapter 4 and 5. No significant differences by two-way ANOVA between DMSO and individual treatments or 
for time dependency within treatments found (n=2). (DMSO = grey, cycloheximide = blue, estradiol = red, 








































































































































































































































































































Figure 63. univariate analysis of signalling lipids in 2D media. Colours indicate same treatment as indicated in 
chapter 4 and 5. No significant differences by two-way ANOVA between DMSO and individual treatments or for 
time dependency within treatments found n=2). (DMSO = grey, cycloheximide = blue, estradiol = red, bosentan 

















































































































































































































































































Figure 64. Univariate analysis of signalling lipids in 3D cells. Colours indicate same treatment as indicated in 
chapter 4 and 5.  No significant differences by two-way ANOVA between DMSO and individual treatments or for 
time dependency within treatments found (n=2). (DMSO = grey, cycloheximide = blue, estradiol = red, bosentan 







































































































































































































































































































Figure 65. Univariate analysis of signalling lipids in 3D media. Colours indicate same treatment as indicated in 
chapter 4 and 5. (n=2). Significance indicated with *: p > 0.05. (DMSO = grey, cycloheximide = blue, estradiol = 











6.3 Discussion of the results. 
These analyses with cultured hepatocytes provided novel insights into the response of 
hepatocytes to stress factors such as the exposure to drugs, but unfortunately large portions 
of signalling pathways that are only present in other cells such as the liver specific 
macrophages, known as Kupffer cells were left out due to the absence of these cells. Kupffer 
cells are responsible for defence and liver disease [129].  We should, therefore, be careful 
with the assessment of conclusions made in this chapter.  
Multivariate analysis revealed a different metabolic fingerprints between 2D and 3D cell data 
in signalling lipids with a strong indication that 3D cells contain higher concentrations of 
signalling lipids; this finding was confirmed in the univariate analysis. The elevation in 
signalling lipids in the 3D cells could be due to the differences in enzyme and protein 
expression in the 3D cultured cells. The latter might be able to imitate normal physiological 
behaviour while the 2D cultured cells are less able to do so [20,130]. While PHH are 
undoubtedly the best choice for investigating liver toxicity, the absence of other cell types, 
especially Kupffer cells, is a major limitation. Kupffer cells do not only have the task of 
mediating inflammation but also have a protective role [131]. We expected the cells treated 
with compounds to show significant effects in the activation of inflammatory and anti-
inflammatory pathways of the signalling lipids and hint at bile acid background processes in 
cell toxicity. However, our treatments of the cells do not show any significant effect, due to 
the possible absence of Kupffer cells described above. It could however also be that there is 
a direct effect of the bile acids to toxicity, but it is unlikely as bile acids such as DCA have been 
shown to have effect on signalling lipids such as sphingomyelin, and ceramide [105]. 
The only a significant increase occurred in 9,10-DiHOME after 72 hrs following the incubation 
with bosentan. 9,10-DiHOME can be synthesized as a result of inflammation and oxidative 
stress and has been proposed as diagnostic marker for intra cholestatic diseases in humans 
[132,133]. Surprisingly this could be an early indicator of oxidative stress and identify which 
BSEP inhibitors will cause oxidative stress. Hence, the production of 9,10-DiHOME could be 
used as a criterium to exclude compounds from further drug development. Elisa kits for 9, 10-
DiHOME detection already exist for the detection in plasma, serum and bronchoalveolar 
lavage fluid to investigate chronic obstructive pulmonary disease (COPD) and other 




This is a novel approach into looking into toxicity of compounds, which will require further 
research before a good conclusion can be made. It would be beneficial to consider co-cultures 
of PHH and Kupffer cells for further investigating lipid signalling and, where possible, to 









7.1 Summary and conclusions for each chapter  
Chapter 3 the details of BSEPs ability to transport TCA and GCA were described in the presence 
and absence of compounds. We used radio-labelled TCA and GCA to measure the 
accumulation in ISOVs containing BSEP. By changing the conditions of the assay used by 
pharmaceutical companies, we were able to investigate the mechanism of inhibition by which 
the compounds influence bile acid transport. From the experiments we were able to draw the 
following conclusions:  
1.) The IC50 by which compounds inhibit BSEP-mediated TCA transport does not directly relate 
to the toxicity of the compound. 
2.) The compounds tested, have different mechanisms of inhibition. This could explain why 
some might be non-toxic despite being strong BSEP inhibitors.  
3.) Transport of GCA is negatively influenced by the presence of Mg2+. 
4.) In the absence of Mg2+ compounds do not interfere with BSEP’s ability to transport GCA.  
Chapter 4 describes the use of 2D and 3D cultured cells in accessing toxicity of Bosentan, 
cycloheximide, clobetasol propionate and estradiol. Since cycloheximide and estradiol were 
reported to not inhibit BSEP directly but to influence the expression and localisation of BSEP 
in hepatocytes, we also investigated the localisation of BSEP in the cells via fluorescent 
staining. Lastly, we used a total bile acid kit to investigate the effect of our treatments on the 
total bile acid concentration within the hepatocyte cultures and the media. The conclusions 
we drew from this chapter were: 
1.) Toxicity of compounds appeared to be donor dependent rather than dependent on culture.  
2.) Staining of BSEP and analysing its localisation is a viable method to investigate the effect 
of compounds on BSEP expression.  
3.) The ability of compounds to increase or decrease BSEP expression in the membrane did not 
correlate with total bile acid accumulation within the cell, indicating that other transporters 




4.) Total bile acid concentration did not correlate with toxicity in hepatocytes, demonstrating 
that the bile acid pool composition might be more important than the total bile acid 
concentration.  
Chapter 5 investigates the effect of the drug treatments on the individual bile acid levels 
within the PHH cultures. With the use of multivariate analysis and univariate analysis we were 
able to see the effects of bosentan, cycloheximide, clobetasol propionate and estradiol on 
individual bile acids. We were further able to study the effect of time on the conjugation of 
bile acids. The conclusions from this chapter were:  
1.) 2D cell, 2D media, 3D cell and 3D media samples each have a unique metabolic bile acid 
fingerprint, indicating that type of culture influences the fingerprint. 
2.) 2D cells and 3D cells are both able to conjugate bile acids in a time dependent manner. 
3.) Drug treatments can significantly change the bile acid pool composition.  
4.) Several secondary bile acids were detected within the samples, the most prominent one 
being DCA.  
Chapter 6 examines the influence of the selected drug treatments on different signalling lipids. 
2D and 3D hepatocyte cultures were compared and the conclusions from this chapter were 
as follows:  
1.) 2D cell, 2D media, 3D cell and 3D media each had a unique metabolic signalling lipid 
fingerprint, showing that metabolic profiling can identify the origin of the sample and 
culturing type. 
2.) Signalling pathways are activated by the different treatments, but whether this is due to 
bile acids and/or to other molecules is unknown. 
3.) Multivariate analysis of individual treatments in 2D cell, 2D media and 3D cells was not 
possible due to the lack in variation, indicating that these samples do not have an individual 
metabolic fingerprint.  






My research aims to improve the understanding of how the inhibition of BSEP activity 
contributes to DILI and improves the prediction of compounds that will cause liver injury as 
well as identify compounds that will not.  
The current standard includes a panel which takes into account the IC50 of BSEP inhibition as 
well as toxicity of cell cultures and the total compound that would be available in the patient 
[15]. Several in silico methods are already able to predict the likeliness of drugs inhibiting 
BSEP [134]. However as this is only one step up from in vitro testing of BSEP inhibition, these 
methods alone are unlikely to predict DILI in humans [135]. To improve the prediction of DILI-
inducing compounds, we need to consider that the cell is a complex system and that drugs 
can influence cells at a multitude of levels. With regards to BSEP and bile acids, drugs can: 1.) 
affect BSEP’s ability to transport bile acids, 2.) affect total BSEP expression, 3.) affect the 
localisation of BSEP at the membrane or in the endosomes inside the cell, or 4.) induce 
changes in the bile acid pool composition [43,44]. In whole organisms we also need to 
consider that other cells can have an ameliorating effect on hepatocytes, either by stimulating 
inflammatory processes or by preventing toxicity through exerting a rescuing effect [129,131].  
One way by which pharmaceutical companies have worked on improving the prediction of 
DILI, is by combining all the gathered information and use machine learning to predict drug 
effects. Using machine learning methods to predict in-silico toxicity has previously been 
stated to be the future [136]. Machine learning describes the scientific study that computer 
systems use to perform a specific task without using explicit instructions. Instead it relies on 
large quantities of information to set up its own set of rules. So, with this, there is already a 
limitation. For machine learning to work there is a large quantity of training data necessary, 
this data is then used to set-up the rules applied by the computer to differentiate between 
possible toxic effects of compounds [136]. The success rate of these approaches have been 
shown to improve over time. Recently AstraZeneca showed an improvement of Dili 
predictions with Bayesian machine learning [137]. The model they use is based on 
physicochemical properties, IC50 of drug-induced BSEP inhibition in ISOVs, toxicity assays from 
different cell systems, and the maximum plasma concentration of the drug that is reached 




sensitivity, and 85% specificity. The model was also able to predict 92% of compounds that 
will cause DILI and 78 % that will not [137].  
My data could prove invaluable to training machine learning algorithms by adding 
mechanisms of drug-induced inhibition of BSEP. The results from chapter 1 indicates that 
BSEP inhibition occurs in different ways, which could explain why toxicity happens regardless 
of BSEP inhibition in the case of clobetasol propionate. Clobetasol propionate was proven to 
be more inhibitory than bosentan when looking at TCA transport. However, with regards to 
toxicity, bosentan causes liver injury while clobetasol propionate does not [15].  
Non-competitive inhibition is more dangerous than competitive inhibition because it cannot 
be overcome by increasing the substrate concentration. With competitive inhibition the 
increase of bile acid would at some point compete away the inhibitory compound. However, 
non-competitive inhibition is independent of bile acid concentration or composition [138]. 
However, either due to the amount of work involved or the difficulty in establishing accurate 
Km and Vmax values in the presence of drug candidates, this type of analysis is not commonly 
done [74]. A novel biochemical assay to analyse the type of inhibition was established, and it 
showed that bosentan, cyclosporin A, and clobetasol propionate act as competitive or non-
competitive inhibitors, and that alpidem might act as an uncompetitive inhibitor. This data is 
based on concentrations where drugs cause 50% of total inhibition. However, this result does 
completely explain the severity of the effects of the drugs in inducing liver injury. Bosentan 
alpidem and cyclosporine A are considered dangerous and cause liver injury while clobetasol 
propionate does not cause any injury. Due to its propensity to not cause liver damage 
clobetasol propionate was expected to be either a competitive or mixed competitive 
inhibitor, while the other drugs were expected to be non or mixed competitive inhibitors. 
There is however an argument against the use of TCA in these kinetic experiments. TCA, while 
used the most in analyses of BSEP-mediated transport, is not the most abundant bile acid or 
the most appropriate bile acid to investigate [75]. GCA is more appropriate, as the conjugation 
rate between glyco and tauro is approximately 3 glyco- to 1 tauro-conjugation within the 
hepatocyte. Previous investigations suggested that no difference exists between TCA and GCA 
transport [71,139,140]. However, anecdotally, several experts and sources stated the 
difficulty of using radiolabelled GCA in transport studies but it was attempted anyway. During 




ions are present in all the buffers used to analyse BSEP mediated transport at both AZ as well 
in the literature. Mg2+ is the fourth most common ion in human and is influenced in 
concentration by drugs such as antibiotics or simple dietary uptake [141,142] Drugs can 
negatively influence the uptake of magnesium from food by utilizing the same uptake systems 
[141]. Another source besides food is the availability of over-the-counter magnesium 
supplements, these supplements currently do not come with many warnings and a literature 
search on PubMed revealed no studies into the health effects of long-term exposure to these 
supplements or how many people are taking term regularly. “webmd.com” only states mild 
warnings for previously established conditions 
(https://www.webmd.com/vitamins/ai/ingredientmono-998/magnesium), but these 
warnings do not relate to liver injury. The influence of Mg2+ on bile acids as well as the 
influence of other physiologically relevant ions on bile acid transport (such as K+ and Ca2+) 
needs further investigation. Both of these ions have already been shown to influence the free 
pools of bile acids in hepatocytes. DCA is a secondary bile acid that can induce calcium 
signalling [105]. On the other hand, TCA, UDCA [96] and other bile acids have been reported 
to influence the excretion is sodium and potassium ions. Thus, a secretory link exists and this 
is also consistent with the Mg2+-GCA effects that is described in this thesis [143]. It is 
interesting to note that previous research in 1994 found that intracellular increases in 
magnesium promoted GDCA induced apoptosis in rat [144], but little to no further 
investigation has been undertaken in Mg2+’s influence on bile acid transport. Considering both 
the previous finding in rats and the data in this thesis show an effect on a glyco-conjugated 
bile acids, it should be investigated if the effect is dependent due to the glyco-group. Currently 
only radiolabelled GCA and TCA are commercially available, so in order to investigate the 
effect of inorganic ions on the transport of other bile acids by BSEP, a new assay needs to be 
developed. Whereas radiolabelled bile acids other than TCA and GCA could possibly be 
synthesized, a non-radiolabelled assay would be preferred. One possibility is to use 
fluorescent-labelled bile acids or use assay kits that can change bile acids into a fluorescent 
signal, such an assay is currently being optimised in the hope to use the information gathered 
from Chapter 5 to prioritise bile acids that are relevant to this investigation.  
In the introduction to Chapter 1.1.1, the current standard in pre-clinal development of 




passing a panel of tests. However, in the same chapter the limitations in these studies were 
described. One of these limitations is the use of immortalised cell lines rather than primary 
cells. The main important difference that was considered previously, was that immortalised 
cell lines can proliferate (giving you a near endless supply of cells) whereas primary human 
hepatocytes are unable to do so. However, in recent literature [96,145–148] profound 
differences were observed between the two cell types in gene expression, enzyme expression 
and protein expression [146], Primary cells therefore are more comparable to humans, but in 
traditional mono-layers cultures of PHH the cells rapidly dedifferentiate and lose their hepatic 
functions [145]. To prevent this dedifferentiation, the cells can either be cultured as 2D 
sandwich cultures with a matrix gel overlay (that causes cell polarisation), or as 3D spheroid 
models (microtissues) or microfluidic systems (liver on a chip) [149,150]. In this PhD work  2D 
sandwich and 3D cultured PHH were compared to establish the effect of selected compounds 
on toxicity, BSEP expression, total bile acid concentration, bile acid metabolomics and 
signalling lipids. A large study in which long term toxicity in 2D cultures was compared with 
3D cultures found that 3D cultures are more sensitive to toxicity in the long term (14 days 
culture) [145]. However, in this study donor specific effects were found to be more important, 
which could be in agreement with previous literature stating the importance of 
polymorphisms in Cyp450 enzymes [82]. With regards to bile acid metabolomics, 3D cells 
were found to have a closer resemblance to the actual physiological bile acid pool in humans 
than 2D cultured PHH. As our system does not contain gut microbiota responsible for 
transforming primary bile acids into secondary bile acids, the entire bile acid pool could not 
be investigated. Bile acid profiling receives more attention at present time because bile acids 
have been shown to be involved in liver and colon cancer [108,151], cardio-protection in the 
form of UDCA [96], and regulation of inflammation [152]. Furthermore, bile acids show 
significant changes in the brain of Alzheimer patients [153]. Although this work able to 
identify several significant changes in bile acids, no specific conclusion regarding toxicity could 
be drawn.  
A second major finding was the presence of secondary bile acids in the experimental samples. 
Previous literature states that the occurrence of secondary bile acids in hepatocyte cultures 
was due to their presence in FCS used to preincubate the cells. During this time the cells are 




them to a level in the cell at which they are detectable [103]. Either way DCA is known as one 
of the most toxic bile acid and its presence in PHH cultures was an unexpected advantage in 
this study when investigating toxicity [105,154,155]. 
Compared to ISOVs, in cells you are not only looking at the transport activity of BSEP but also 
take into account that several other transporters are influenced by the change in bile acid 
pool concentrations. Uptake of bile acids at the basolateral side of hepatocytes is facilitated 
by OATP2, mEH and NTCP whereas, in addition to BSEP, MRP2 is able to export bile acids at 
the apical side of the hepatocytes [156]. Currently, many studies investigate the effect of 
compounds and mutations by looking at mRNA levels and quantitative western blots of BSEP, 
this is not completely accurate. BSEP is continuously recycled from the apical membrane to 
Rab 11-positive vesicles in the cytoplasm. When the need arises the hepatocyte is able to 
recruit a large amount of BSEP from these vesicles to the membrane [157]. Our staining 
revealed that compounds can influence the localisation of BSEP within the cell. This manner 
of investigating transporter expression is a more accurate way of looking at BSEP expression 
because only BSEP within the plasma membrane is involved in bile acid efflux from the cell. 
However, for 3D spheroids some optimisation is still required. Firstly, due to the size of the 
spheroids, more diffusion of the antibodies through the microtissues is required than in 2D 
cultured cells. Secondly, even confocal microscopes have a limitation in depth; it is therefore 
necessary to clarify the cells prior to imaging [59] (cells are made transparent), which enables 
the confocal microscope to look through larger structures [158]. While this is regularly done 
for tissues, the application of these methods are more difficult for spheroids which are not 
attached and can be lost in any steps that remove liquid. BSEP staining and quantification via 
confocal microscopy can easily be adapted for large scale investigation and should be 
considered to be included in any future toxicity study, as well as in any machine learning 
panel.  
Finally, lipid signalling was investigated. Lipids are important in the communication of the 
stress signals not only within the cell but also to other cells, such as macrophages, that are 
responsible for immune responses and protection. In the liver, macrophages are Kupffer cells 
that have been proven to have protective effects in acetaminophen-induced liver injury [131]. 
Because we looked at monocultures we now know how hepatocytes react to bosentan, 




signalling pathways happen within the Kupffer cells. Since signalling lipids go from cell to cell 
and our culture only contained hepatocytes, the signalling lipids show little to no significant 
difference in response to the different compounds. To make a proper comparison between 
in vitro and physiological process, the metabolomics of signalling lipid should be studied 
within co-cultures of hepatocytes and Kupffer cells [159]. These co-cultures have been proven 
to be more robust and relevant to investigate inflammatory and toxic effects of compounds 
[159]. The FDA also encourages to investigate such cocultures and the frequency of such 
studies will therefore most likely increase in the future. The FDA’s model for a co-culture 
showed a continued metabolic capacity characteristic of PHH, an ability to secrete pro-
inflammatory cytokines in response to LPS, and responses to interleukin species for 2 weeks. 
Although the co-culture is currently not well established enough to be a valid toxicity assay, 
the FDA encourages to investigate such co-cultures and the frequency of such studies will 
therefore most likely increase in the future. The continued interest into these cultures is also 
evident from the advances that are currently being made towards organ investigations 
instead of simple cell systems. Current spheroid systems are the golden standard for 
investigating toxicity. Liver on a chip is already under development [160]; these chips use 
microfluidic systems to imitate the flow of body liquids. The next step is to combine several 
cell types to create an organ on a chip , which when linked together would create a human 











7.3 Future experiments:  
Considering the discussion of this work, the following experiments are proposed that will 
increase our understanding of BSEP and bile acid-mediated toxicity in hepatocytes:  
1.) Use the A444V, W330A, Y337A, Y772A, R1033A and T1029A BSEP mutants generated in 
this PhD research to investigate their effects on the kinetics of TCA and GCA transport.  
2.) Develop a high-throughput non-radioactive assay to investigate the effect of mutations 
and compounds on BSEP’s efficiency to transport different bile acids.  
3.) Investigate the effect of physiologically relevant ions such as calcium, potassium and 
chloride on BSEPs ability to transport bile acids. 
4.) Investigate the effect of co-cultures of hepatocytes and Kupffer cells on cell toxicity, BSEP 
localisation, bile acid metabolism and lipid signalling. 
5.) Establish the origin of the secondary bile acid DCA in hepatocytes. Is it possible that human 
cells have a direct pathway for DCA synthesis? 
6.) Combine the information obtained under point 1, 2, and 3 with literature data on BSEP to 
carry out a non-linear regression analysis that investigates the correlation between mutation 
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Appendix A. Summary of mutations  
*Mutations without a literature refence were mined from 
https://www.ncbi.nlm.nih.gov/variation/view/  
** missense mutations without description are only mention in article but not investigated 
further.  
mutation  description 
M1V Heterozygous for M1V and R387H without other mutations, no information 




R52W Heterozygous for R52W with a second mutation at H615R had reduced staining 




L71H no information about symptoms of the patient. L71H was present in 






Y93S Y93S together with V597L and R1128C in patients presenting with history of 




W114R [34][51] heterozygous for this mutation no second mutation was found, biliary 





E135K [23,34,50,164] has been reported to produce mature BSEP protein but with 
some reduction in the protein levels. [50] while it should not produce 
structural changes the E135K mutation might cause changes in N-glycosylation 
of the nearby asparagines 109, 116, 122, 125 that have been reported to 
undergo the post-translational modification.  
E137K present in a patient with recurrent cholestasis 6Y, together with a P740Qfs*6 
[34,163] Immunostaining of BSEP was not present  
Y157C [34] 




A167T Biliare BA 0.5, BSEP not present in immunohistochemistry staining [51] was 
identified in patient together with G1058HfsX38 on the second allele and 
together was also determined to be heterozygous for V444A and heterozygous 






M183V [34,51,166] patient positive heterozygous with second mutation G455E, 
harbouring the homozygous ABCB11 mutation p.V444A and harboured, the 
homozygous ATP8B1 mutation p.R952Q. no further information available.  
W186G 
 




A212T Patient died at the age of 1.5Y. immunostaining was not done and A212T was 
present in combination with Q546H and E238D [163] 
M217R [34] 
R223C [34] 
S226L Homozygous for this mutations as well as homozygous for V444A, no 
information about biliary flow or staining at canalicular site [51], no canalicular 
staining present. Biliary BA reduced.  
no information about symptoms of the patient. L71H was present in 




G238V Homozygous for this mutation, [51] 








A257V [31] patient that was heterozygous for this mutation and G982R mutation and 






E283D Patient died at the age of 1.5Y. immunostaining was not done and A212T was 
















E297G a decrease in half-life may shorten residency of BSEP at the canalicular 
membrane[34], [170] A higher proportion of short-chain ubiquitination was 
observed in BSEPE297G and BSEPD482G as compared to wild type BSEP suggesting 
that ubiquitin dependent degradation is involved in the reduction of 
transporter half live [171] 
patient that was homozygous for this mutation and V444A showed reduced 
(0.80) biliary BA concentration, BSEP staining at canaliculi was negative.  
A second patient heterozygous for E297G and S699P with the homozygous 
V444A mutation was identified, no information about biliary BA concentration 
or BSEP staining. [51] 
 
BSEP genotype could also have a predictive value because the PFIC2 patient 
with BD success had a homozygous p.E297G mutation and two other PFIC2 
patients with BD partial failure harboured on one allele the p.E297G mutation. 
[51] 
This mutant is known to be associated with impaired membrane trafficking but 
to retain some transport activity when correctly targeted. The with impaired 
membrane trafficking but to retain some transport activity when correctly 
targeted [51]. 
 
Led to a reduced expression at the apical membrane, when expressed in MDCK 
cells [23]. Homozygosity is linked to PFIC-2, heterozygosity was detected in 















G374S Siblings with the homozygous mutation, development of liver cirrhosis was 
delayed and occurred after childhood. Amino acid 374 is part of the putative 
sixth transmembrane helix and lies in vicinity to the channel pore, which may 
explain the severely reduced transport capacity of BSEP [23,34,177] showed 
an increased membrane expression of BSEP (as compared to wild type BSEP) 








R387H Heterozygous for M1V and R387H without other mutations, no information 



















V444A The frequent BSEP polymorphism p.V444A represents the mildest form of 
BSEP deficiency[23]. The allele frequency of c.1331T>C (p. V444A) was 76% in 
patients with DILI as compared to 59% in controls with an odds ratio of 4.0 
[23]. 
Has been linked to ICP. The C-allele is more frequent in ICP-patients as 
compared to healthy pregnant women [34] and also predisposes for the 
development of drug-induced liver injury (DILI). common explanation for the 
relation between p.V444A and ICP or DILI is a decreased expression of BSEP in 
the presence of the polymorphism as shown in a small cohort. 
BSEP expression may be severely reduced in MDR3- dependent ICP when 
p.V444A is present and p.V444A may influence development of liver fibrosis in 
patients with chronic hepatitis C infection. 
In a recent study a higher prevalence of p.V444A was observed in 
Cholangiocarcinoma-patients. 
Patients with ICP or CIC have higher prevalence of V444A [23]. If V444A was 
present in combination with G982R and Y818F, complete degradation of triple-
mutated BSEP via ERAD was observed [23]. 
Further-more, hepatitis C infected patients, who are homozygous for valine of 
p.V444A have less severe liver fibrosis and some but not all HCV-cohorts show 
better treatment responses towards interferon/ribavirin treatment [23].  
V444D [23,31,34,51,53,55,72,164,166–168,177–187] A role of BSEP for the 
development of CC was also suggested on the basis of an association to the 
BSEP polymorphism V444A in a study of 172 CC patients. [188] frequency 
~50%, which may occur iso allelic to mutations, strongly increases ERAD, as 
shown in expression studies of cloned BSEP [189]  
V444G [34] 
V454L [34] 
G455E patient positive heterozygous with second mutation G455E, harboring the 
homozygous ABCB11 mutation p.V444A and harboured, the homozygous 



















D482G A decrease in half-life may shorten residency of BSEP at the canalicular 
membrane [34] [170]A higher proportion of short-chain ubiquitination was 
observed in BSEPE297G and BSEPD482G as compared to wild type BSEP suggesting 
that ubiquitin dependent degradation is involved in the reduction of 
transporter half live [171] 
patient homozygous for D482G showed negative staining for IHC anti-BSEP at 
canaliculi [50] 
Homozygosity was linked to PFIC-2 and heterozygosity detected in 1.4% of 491 
patients with ICP [23] splicing and exon skipping was reported for this typical 















A523G two sisters with likely pathogenic homozygous mutation: both had a history of 







I541L Two patients both homozygous for I541L, was negative for IHC staining at 
canaliculi [50] 
Q546H Patient died at the age of 1.5Y. immunostaining was not done and A212T was 

















V567I [23,34,168,186]  
A570T Heterozygous for I669V with a second mutation at A570T, was negative for IHC 
BSEP staining. [50] 
A patient homozygous for this mutation was negative for IHC staining for 
BSEP[50] 
This mutation introduces a steric hindrance that interferes with the packing of 
three helices formed by residues 512-519, 525-534 and 561-575 in the first 
ABC transporter domain 
 
The two ‘BRIC-2 mutations’ p.A570T and p.R1050C had lower expression levels 
than the ‘ICP mutation’ p.N591S, but higher expression levels as compared to 













N591S Canalicular expression of BSEP with the ‘‘typical’’ ICP mutation p.N591S was 
higher than that of the BRIC-2 (p.A570T, p.R1050 C) or PFIC-2 mutations 
(p.D482G, p.E297G) [34],6] Recently, a neonate has been described with 
homozygosity for p.N591S and, in addition, a homozygous mutation (p.H338Y) 
in the SLC27A5 gene. SLC27A5. This child presented with liver fibrosis within 
the first year of life, while a sibling was free of symptoms although it had the 
same homozygous SLC27A5 mutation, while it was heterozygous for p.N591S 
[151], demonstrating a ‘‘dose effect’’ of N591S. [34]  
E592Q [192] 
S593R [34] 
V597L [34], Y93S together with V597L and R1128C in patients presenting with history 




H615R Heterozygous for R52W with a second mutation at H615R had reduced staining 
for IHC anti-BSEP at canaliculi [50] H615R was inherited from the mother (look 
up for negative effects, while R52W was a de novo mutation.  
R616G In particular, ABCB11 p.R616G is suspicious for changing the physicochemical 
properties of the resulting protein (highest Grantham score of 125) is probably 
deleterious according to the low SIFT value (0.01), is supposed to affect protein 
function because of its high PSIC score, and is evolutionarily less favourable 
considering the negative BLOSUM62 value, although sequence alignments 
indicated that p.R616G is located in a probably less deleterious, evolutionarily 











I669V Heterozygous for I669V with a second mutation at A570T, was negative for IHC 
BSEP staining. [50] 
D676Y [34] 




R698H [34] heterozygous for R698H and the heterozygous ABCB11 mutation p.V444A, 
no information about biliary BA concentration but focal positive and negative 
canalicular staining [51] 
A second patient heterozygous for R698H, but with homozygous ABCB11 
mutation p.V444A and heterozygous ABCB11 mutation p.M677V, there was no 
information about biliary BA concentration but patient was focal positive and 
negative canalicular staining [51] 
R698C [34,51,55,167,179]  
S699P A patient heterozygous for E297G and S699P with the homozygous V444A 
mutation was identified, no information about biliary BA concentration or 












Y818F [30] caused intracellular retention of BSEP, shown in vitro [6] If V444A was 
present in combination with G982R and Y818F, complete degradation of triple-
mutated BSEP via ERAD was observed [23]  
L827I [34], [23] 
R832C Homozygous for R382 mutations showed negative results for IHC anti-BSEP 


















T923P  [34,193] 
A926P [34] 






R948C Two patients Heterozygous for R948C with a second mutation at S1027R, not 
further information. [50] 
R958Q 
 









G982R A patient that was heterozygous for this mutation and G982R mutation and a 
homozygous mutations for V444A, no further information was available [51]. 
Second patient was heterozygous for this mutation additionally to the silent 
mutation R1001R, and the heterozygous ABCB11 mutation p.V444A, no 
information about biliary BA concentrations but canaliculi staining for BSEP 
was negative.  
 
Led to a reduced expression at the apical membrane, when expressed in MDCK 
cells [23]. Caused intracellular retention of BSEP shown in vitro [23]. If V444A 
was present in combination with G982R and Y818F, complete degradation of 







S1027R Two patients Heterozygous for R948C with a second mutation at S1027R, not 
further information. [50] 
p.S1027R replaces a serine with an arginine residue in a transmembrane helix, 
influencing electrostatic properties and the packing of this helix with adjacent 
transmembrane helices. [50] 
G1032R [34] 
A1044P [34] 
R1050C Analysis of the effects of p.R1050C mutation revealed an important reduction 
in BSEP levels and activity [50] research showed the protein expression is 
reduced by 30 to 50% compared to WT and reduces activity by up to 50% [50] 




It can be seen in article [50] that R1050 (site of the R1050C mutation) is 
engaged in a salt bridge with Glu734, which helps to anchor the short helix 
formed by residues 731–735 to the remainder of the protein structure. [50] 
The two ‘BRIC-2 mutations’ p.A570T and p.R1050C had lower expression levels 
than the ‘ICP mutation’ p.N591S, but higher expression levels as compared to 



















G1116F [23,34] patient heterozygous for G1116F and R387H, homozygous ABCB11 
mutation p.V444A and harbouring compound heterozygous status for ATP8B1 
mutations p.R952Q and p.E429A. there was no information about biliary BA 






R1128H Only mentioned [34]. 
Patient was homozygous for this mutations, showed reduced biliary 
concentration (0.10), canaliculi staining for BSEP was negative. [51] second 
patient was also homozygous for this mutation and showed reduced biliary BA 
concentrations (0.58) and was also negative for BSEP staining at canaliculi.  
A third patient who was homozygous for this mutations and homozygous 
mutation for V444A. (due to drop out no information about biliary BA 
concentration of staining)[51], 
Y93S together with V597L and R1128C in patients presenting with history of 
neonatal jaundice, DIC, ICP, juvenile cholelithiasis, itching [164] 
D1131V [34], [23] 
S1144R [176] By the use of an in vitro minigene approach, interference with splicing 
was shown [34] 
K1145N [34], [23] 
R1153H By the use of an in vitro minigene approach, interference with splicing was 
shown [34] 
Patient with heterozygous for R1153H and R1050C, positive for IHC anti-BSEP 
staining at canaliculi. [50]  
p.R1153H mutation of ABCB11 produces severe splicing alteration 
resulting in only 3% of wild-type-like splicing product. In a patient carrying the 





The p.R1153H produces severe splicing alteration leading to only 3% of WT like 
splicing product [50] The eventual tiny residual fraction of correctly spliced 
BSEP protein is not expected to be capable of proper transport activity, since 
the p.R1153H mutation  
affects residues interacting with and determining the structure of the Walker 
motif in the second ABC transporter domain of BSEP. [50] 

















T1210P Homozygous for this mutation and V444A, showed reduced biliary 













R1231Q By the use of an in vitro minigene approach, interference with splicing was 
shown [34] 



































Appendix B. Accompanying table to figure 8  
Table 13 Mutation counts according to disease and if the mutations are either located in the cytoplasm, 










PFIC2 90 7 18 102 
BRIC2 23 3 1 27 
ICP 7 1 
 
8 
DILI 1 0 0 1 
NFC 12 2 1 15 
No disease  
association 
34 2 2 38 
other 11 2 1 14 
benign 16 0 0 16 
association to more  
than one disease 
108 12 9 132 






























Cyclosporin Clobestasol propionate Alpidem Bosentan
AZFilters U U C B
Molecular Weight 1202.611 466.97 404.333 551.614
CLogP 14.36 3.49 5.581 4.167
CLogP error Very high LogP unrealistic in nature All fragments measured Adjusted (1) from measured value All fragments measured
Polar Surface Area 290.066 86.166 29.96 142.956
Heavy Atom Count 85 32 27 39
Rotatable Bonds 33 4 7 10
H-Bond Donors 5 1 0 2
H-Bond Acceptors 12 4 3 10
Positive charges 0 0 0 0
Basic charges 0 0 0 0
Acid centers 0 0 0 1
IC50 (uM) 0.5 8.5 9.2 38.1
Ki values 9.5 mol/L 0.000012 mol/L
DILI category Cholestatic mixed None Hepatocellular Cholestatic mixed
pioglitazone troglitazone ketoconazole nefazodone
AZFilters C C C C
Molecular Weight 356.439 441.54 531.431 470.007
CLogP 3.533 5.585 3.635 5.725
CLogP error All fragments measured All fragments measured Derived from measured fragment value Calculated fragment value
Polar Surface Area 70.464 92.197 57.825 43.716
Heavy Atom Count 25 31 36 33
Rotatable Bonds 7 6 10 12
H-Bond Donors 1 2 0 0
H-Bond Acceptors 4 5 7 7
Positive charges 0 0 0 0
Basic charges 0 0 1 1
Acid centers 0 0 0 0
IC50 (uM) 0.3 2.7 2.9 4.2
Ki values
DILI category cholestatic mixed cholestatic mixed cholestatic mixed cholestatic mixed
glibenclamide rifamycin SV rosiglitazone fusidic acid
AZFilters C U C U
Molecular Weight 494.004 697.768 357.427 516.709
CLogP 4.239 3.861 3.02 7.284
CLogP error All fragments measured All fragments measured All fragments measured All fragments measured
Polar Surface Area 126.894 218.3 71.338 113.013
Heavy Atom Count 33 50 25 37
Rotatable Bonds 9 12 7 6
H-Bond Donors 3 6 1 2
H-Bond Acceptors 5 11 5 5
Positive charges 0 0 0 0
Basic charges 0 0 0 0
Acid centers 1 2 0 1
IC50 (uM) 5.3 6.3 6.4 11.5
Ki values 27.5 mol/L 31 mol/L 







Molecular Weight 326.429 346.335
CLogP 6.065 3.125
CLogP error All fragments measured Derived from measured fragment value
Polar Surface Area 49.935 112.851
Heavy Atom Count 24 25
Rotatable Bonds 6 4
H-Bond Donors 0 1
H-Bond Acceptors 3 5
Positive charges 0 0
Basic charges 0 0
Acid centers 1 0
IC50 (uM) 18.2 30.7
Ki values
DILI category cholestatic mixed cholestatic mixed
